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Abstract: Atherosclerosis is a chronic inflammatory disease of the vascular wall, characterized by the
proliferation and accumulation of vascular smooth muscle cells (VSMCs) in the intimal layer of the wall.
Previous studies of this laboratory have identified BACE2 (￿-site APP-cleaving enzyme 2) as a gene
expressed at a higher level in atherosclerosis-protected arteries in experimental atherosclerosis. The as-
partyl protease BACE2 is an alternative ￿ secretase which mediates ectodomain shedding of amyloid-￿
precursor protein (APP) and other transmembrane proteins. BACE2 shares high homology with BACE1
at amino acid level. The ￿-secretase BACE1 is predominantly expressed in neuronal cells, and is re-
sponsible of shedding APP resulting in the generation of the neurotoxic amyloid-￿ (A￿) in Alzheimer’s
disease. BACE2 is expressed at low level in the brain but is found to be highly expressed in vascularized
tissues. Moreover, BACE2 preferentially cleaves APP at a different site, resulting in the formation of
a non-amylogenic product. The similarity between Alzheimer’s disease and atherosclerosis and the high
expression of the secretase in atherosclerosis-resistant arteries, led to speculate a role of BACE2 in the
regulation of atherosclerosis. The aim of the present dissertation was to characterize the expression,
regulation and function of BACE2 in VSMCs in vitro and the effect of BACE2 on atherosclerosis in vivo.
This study demonstrates for the first time that BACE2 is expressed in human VSMCs. Using immunoflu-
orescence analysis BACE2 was localized to caveolae, trans-Golgi network and endosomes. Furthermore,
upon stimulation of cell growth, a rapid proteasome-dependent degradation of BACE2 was observed.
Overexpression of BACE2 in VSMCs resulted in inhibition of cell proliferation, and was accompanied
with downregulation of c-jun- and I￿B￿- dependent pro-inflammatory signaling pathways. On the other
hand, downregulation of BACE2 using specific siRNA enhanced proliferation of these cells. To study the
potential role of BACE2 in vivo, mice systemically overexpressing human BACE2 were generated and
than crossed with ApoE-/- mice. The ApoE-/- BACE2-Tg mice had reduced atherosclerosis compared to
ApoE-/- control mice. Furthermore, blood plasma concentrations of the pro- inflammatory cytokine IL-1￿,
cholesterol and lipids were also reduced. These results suggest a protective role of BACE2 in atheroscle-
rosis, by attenuating proliferation of VSMCs, inflammation, and plasma levels of cholesterol and lipids.
Thus, specific induction and activation of BACE2 could provide a novel therapeutic approach to de-
crease progression of atherosclerosis. Atherosklerose ist eine entzündliche, chronische Gefäßkrankheit,
die sich durch Vermehrung und Ablagerung von vaskulären, glatten Muskelzellen in der inneren Schicht
der Arterienwand auszeichnet. In früheren Studien dieses Labors wurde gezeigt, dass BACE2 (￿- site
APP-cleaving enzyme 2) stärker exprimiert wird in Arterien, die gegen Atherosklerose geschützt sind.
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vaskulärem Gewebe exprimiert, wohingegen kaum im Gehirn. Außerdem schneidet BACE2 vorzugsweise
APP an einer anderen Erkennungsequenz, welches zur Entstehung eines nicht amylogenen Produktes
führt. Die Homologie zwischen Morbus Alzheimer und Atherosklerose und die erhöhte Expression von
BACE2 in von Atherosklerose geschütztem vaskulärem Gewebe, legen die Vermutung nahe, dass BACE2
eine Rolle in der Regulation von Atherosklerose spielen könnte. Das Ziel der vorliegenden Dissertation
war die Charakterisierung der Expression, Lokalisation, Regulation und Funktion der Sekretase BACE2
in vaskulären glatten Muskelzellen in vitro. Zusätzlich wurde die Funktion von BACE2 in einem Modell
für Atherosklerose, der ApoE-/- defizienten Maus, in vivo analysiert. In der vorliegenden Arbeit wird
zum ersten Mal gezeigt, dass BACE2 in menschlichen vaskulären glatten Muskelzellen exprimiert wird.
Mit Hilfe der Immunofluoreszenzanalyse konnte bestimmt werden, dass BACE2 sowohl in den Caveolae,
im Trans-Golgi Netzwerk und in den Endosomen vaskulärer glatter Muskelzellen lokalisiert ist. Außer-
dem konnte, nach Stimulation mit Wachstumsfaktoren, ein schneller Proteasom-abhängiger Abbau des
Proteins BACE2 festgestellt werden. Die Überexpression von BACE2 in vaskulären glatten Muskelzellen
führte zur Hemmung der Zellvermehrung. Zusätzlich führte dies zu einer Herunterregulierung von c-jun
und I￿B￿-abhängigen entzündungsfördernden Signalwegen. Die Herunterregulierung der BACE2 Gen-
expression durch eine siRNA Transfektion resultierte in einer erhöhten Zellvermehrung desselben Zell-
typs. Um die Funktion von BACE2 in vivo zu untersuchen, wurden ApoE-/- BACE2 transgene Mäuse
(BACE2-Tg) generiert und mit ApoE-defizienten Mäusen gekreuzt. In den ApoE-/- BACE2-Tg Mäusen
konnte, im Vergleich zu den ApoE-/- Kontrollmäusen, eine Reduktion der atherosklerotischen Plaques
festgestellt werden. Darüber hinaus war die Konzentration von entzündungsfördernden Zytokinen wie
auch die Konzentration von Cholesterin und Fette im Blutplasma verringert. Die vorliegenden Ergebnisse
deuten darauf hin, dass BACE2 anti- proliferative und anti-inflammatorische Eigenschaften in Bezug auf
Atherosklerose aufweist. Spezifische Induktion und Aktivierung von BACE2 könnte ein neuer thera-
peutischer Ansatz zur Behandlung atherosklerotischer Erkrankungen sein.
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-163871
Dissertation
Published Version
Originally published at:
Minotti, Roberta. Characterization of BACE2 as a modulator of vascular smooth muscle cell function
and atherosclerosis. 2009, University of Zurich, Faculty of Science.
2
 Characterization of BACE2 as a Modulator of 
Vascular Smooth Muscle Cell Function 
and Atherosclerosis 
 
 
Dissertation  
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
 
 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
von 
 
 
ROBERTA MINOTTI 
von Giubiasco TI 
 
 
Promotionskomitee 
 
Prof. Dr. Alex Hajnal (Vorsitz)  
Prof. Dr. Matthias Barton (Leitung der Dissertation) 
Prof. Dr. Ruedi Aebersold  
 
 
Zürich, 2009 
TABLE OF CONTENTS   
 2
TABLE OF CONTENTS 
 
TABLE OF CONTENTS........................................................................................................... 2 
ABBREVIATIONS.................................................................................................................... 4 
SUMMARY ............................................................................................................................... 6 
ZUSAMMENFASSUNG........................................................................................................... 7 
1. INTRODUCTION.................................................................................................................. 9 
1.1 The Cardiovascular System.............................................................................................. 9 
1.1.1 Function of the Blood.............................................................................................. 10 
1.1.2 Arterial Structure..................................................................................................... 11 
1.1.3 Cells of the Arterial Wall ........................................................................................ 12 
1.1.3.1 Endothelial Cells .......................................................................................... 12 
1.1.3.2 Vascular Smooth Muscle Cells..................................................................... 13 
1.2 Cardiovascular Disease and Atherosclerosis.................................................................. 14 
1.2.1 Risk Factors of Atherosclerosis............................................................................... 15 
1.2.1.1 Controllable/Treatable Risk Factors ........................................................... 15 
1.2.1.2 Uncontrollable Risk Factors ........................................................................ 15 
1.2.2 Pathogenesis of Atherosclerosis.............................................................................. 16 
1.2.2.1 Endothelial Dysfunction (Lesion type I to III) ............................................. 17 
1.2.2.2 Fatty Streak Formation (Lesion type II) ...................................................... 18 
1.2.2.3 Intermediate and Atheroma Lesion Formation (Lesion type III and IV) ..... 18 
1.2.2.4 Fibroatheroma Lesion (Lesion type V) and Vulnerable Plaque .................. 20 
1.2.2.5 Complicated Lesion (Lesion type VI ) and Plaque Rupture......................... 21 
1.2.3 Inflammation and Atherosclerosis .......................................................................... 22 
1.3 Heterogeneity of Atherosclerosis in Humans................................................................. 25 
1.4 Experimental Models of Atherosclerosis ....................................................................... 25 
1.4.1 Experimental Model of Atherosclerosis in Vitro .................................................... 25 
1.4.2 Experimental Model of Atherosclerosis in Vivo ..................................................... 26 
1.5 Candidate Gene Affecting Atherosclerosis .................................................................... 28 
1.5.1 Identification of a Secretase as a Candidate Gene Protecting From Atherosclerosis
.......................................................................................................................................... 30 
1.6 Biological Importance of Secretases .............................................................................. 30 
1.6.1 The Secretase Family .............................................................................................. 34 
1.6.2 β-site APP-Cleaving Enzyme 2............................................................................... 36 
TABLE OF CONTENTS   
 3
1.7 Aim of the Project .......................................................................................................... 39 
1.8 References ...................................................................................................................... 40 
2. MANUSCRIPT DRAFT...................................................................................................... 54 
3. EXPERIMENTS NOT INCLUDED IN THE MANUSCRIPT DRAFT........................... 100 
3.1 In Vitro Experiments .................................................................................................... 100 
3.1.1 Introduction ........................................................................................................... 100 
3.1.2 Methods................................................................................................................. 100 
3.1.3 Results ................................................................................................................... 101 
3.1.4 Discussion ............................................................................................................. 104 
3.2 In Vivo Experiments .................................................................................................... 106 
3.2.1 Introduction ........................................................................................................... 106 
3.2.2 Methods................................................................................................................. 106 
3.2.3 Results ................................................................................................................... 108 
3.2.4 Discussion ............................................................................................................. 112 
3.3 References .................................................................................................................... 114 
4. EXTENDED DISCUSSION.............................................................................................. 117 
4.1 Regulation of BACE2 Expression................................................................................ 117 
4.2 BACE2, an Alternative α-Secretase: Role of α-Secretases in Atherosclerosis............ 117 
4.3 Possible Role of BACE2 in Cytokine Receptor Shedding........................................... 118 
4.4 In vivo relevance?......................................................................................................... 120 
4.5 Possible Roles of BACE2 in Regulation of Lipid and Cholesterol Metabolism ......... 122 
4.5 Conclusion and Clinical Implications .......................................................................... 124 
4.6 References .................................................................................................................... 126 
ACKNOWLEDGEMENTS ................................................................................................... 130 
CURRICULUM VITAE ........................................................................................................ 132 
ABBREVIATIONS   
 4
ABBREVIATIONS 
 
Aβ     Amyloid-β 
ADAM    A disintegrin and metalloproteases  
Akt/PKB   Protein kinase B 
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BACE1   β-secretase cleavage enzyme 1  
BACE2    β-site APP-cleaving enzyme 2  
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CREB    cAMP response element-binding protein 
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ERK1/2   Extracellular signal-regulated kinases  
GH     Growth hormone  
GSK3    Glycogen synthase kinase 3 α/β 
GTT    Glucose tolerance test 
HDL     High density lipoprotein 
HGF     Hepatocyte growth factor 
ICAM-1   Intracellular adhesion molecule-1  
IFN-γ     Interferon-γ 
IGF-1    Insulin-like growth factor-1  
IκBα    IκB kinase α  
IL-1    Interleukin-1 
IL-1R1   IL-1 receptor type I  
IL-1R2     IL-1 receptor type II  
IL-6    Interleukin-6 
IRS-1    Insulin receptor substrate 1  
JNK     c-Jun N-terminal kinases 
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LDL     Low density lipoprotein  
LRP1    Low-density lipoprotein receptor related protein  
MAPK s   Mitogen-activated protein kinases  
MCP-1   Monocyte chemotactic protein 1 
MIF     Macrophage migration inhibitory factor 
M-CSF   Macrophage colony-stimulating factor 
NF-κB    Nuclear factor κB 
p38     P38 mitogen-activated protein kinase 
PDGF     Platelet derived growth factor 
PI3K     Phosphoinositide-3 kinase  
p70S6 kinase   70 kDa ribosomal S6 kinase 
PVR     Peripheral vascular resistance  
sAPP    Soluble amyloid precursor protein 
TGF-α    Transforming growth factor-α 
TGF-β    Transforming growth factor β  
TGN    Trans-Golgi network 
TNF-α    Tumor necrosis factor-α  
VCAM    Vascular adhesion molecule 
VSMCs   Vascular smooth muscle cells 
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SUMMARY 
 
Atherosclerosis is a chronic inflammatory disease of the vascular wall, characterized by the 
proliferation and accumulation of vascular smooth muscle cells (VSMCs) in the intimal layer 
of the wall. Previous studies of this laboratory have identified BACE2 (β-site APP-cleaving 
enzyme 2) as a gene expressed at a higher level in atherosclerosis-protected arteries in 
experimental atherosclerosis. The aspartyl protease BACE2 is an alternative  secretase 
which mediates ectodomain shedding of amyloid-β precursor protein (APP) and other 
transmembrane proteins. BACE2 shares high homology with BACE1 at amino acid level. The 
β-secretase BACE1 is predominantly expressed in neuronal cells, and is responsible of 
shedding APP resulting in the generation of the neurotoxic amyloid-β (Aβ) in Alzheimer’s 
disease. BACE2 is expressed at low level in the brain but is found to be highly expressed in 
vascularized tissues. Moreover, BACE2 preferentially cleaves APP at a different site, 
resulting in the formation of a non-amylogenic product. The similarity between Alzheimer’s 
disease and atherosclerosis and the high expression of the secretase in atherosclerosis-resistant 
arteries, led to speculate a role of BACE2 in the regulation of atherosclerosis. The aim of the 
present dissertation was to characterize the expression, regulation and function of BACE2 in 
VSMCs in vitro and the effect of BACE2 on atherosclerosis in vivo. 
This study demonstrates for the first time that BACE2 is expressed in human VSMCs. Using 
immunofluorescence analysis BACE2 was localized to caveolae, trans-Golgi network and 
endosomes. Furthermore, upon stimulation of cell growth, a rapid proteasome-dependent 
degradation of BACE2 was observed. Overexpression of BACE2 in VSMCs resulted in 
inhibition of cell proliferation, and was accompanied with downregulation of c-jun- and IκBα-
dependent pro-inflammatory signaling pathways. On the other hand, downregulation of 
BACE2 using specific siRNA enhanced proliferation of these cells. To study the potential role 
of BACE2 in vivo, mice systemically overexpressing human BACE2 were generated and than 
crossed with ApoE-/- mice. The ApoE-/- BACE2-Tg mice had reduced atherosclerosis 
compared to ApoE-/- control mice. Furthermore, blood plasma concentrations of the pro-
inflammatory cytokine IL-1β, cholesterol and lipids were also reduced. These results suggest 
a protective role of BACE2 in atherosclerosis, by attenuating proliferation of VSMCs, 
inflammation, and plasma levels of cholesterol and lipids. Thus, specific induction and 
activation of BACE2 could provide a novel therapeutic approach to decrease progression of 
atherosclerosis. 
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ZUSAMMENFASSUNG 
 
Atherosklerose ist eine entzündliche, chronische Gefäßkrankheit, die sich durch Vermehrung 
und Ablagerung von vaskulären, glatten Muskelzellen in der inneren Schicht der 
Arterienwand auszeichnet. In früheren Studien dieses Labors wurde gezeigt, dass BACE2 (β-
site APP-cleaving enzyme 2) stärker exprimiert wird in Arterien, die gegen Atherosklerose 
geschützt sind. Die Aspartylprotease BACE2 (β-site APP-cleaving enzyme 2) ist für die 
enzymatische Spaltung der extrazellulären Domäne des Beta-Amyloid Vorläufer Proteins 
(APP) oder anderer transmembraner Proteine verantwortlich. BACE2 weist eine grosse 
Ähnlichkeit in der Aminosäuresequenz zu BACE1 auf. BACE1 wird hauptsächlich in 
Neuronen exprimiert und vermittelt die enzymatische Spaltung des APP, welches zur Bildung 
des neurotoxischen Beta-Amyloid Peptids führt. Das Beta-Amyloid spielt eine entscheidende 
Rolle in der Entstehung von Morbus Alzheimer, einer präsenilen Demenz. BACE2 wird stark 
in vaskulärem Gewebe exprimiert, wohingegen kaum im Gehirn. Außerdem schneidet 
BACE2 vorzugsweise APP an einer anderen Erkennungsequenz, welches zur Entstehung 
eines nicht amylogenen Produktes führt.  
Die Homologie zwischen Morbus Alzheimer und Atherosklerose und die erhöhte Expression 
von BACE2 in von Atherosklerose geschütztem vaskulärem Gewebe, legen die Vermutung 
nahe, dass BACE2 eine Rolle in der Regulation von Atherosklerose spielen könnte. 
Das Ziel der vorliegenden Dissertation war die Charakterisierung der Expression, 
Lokalisation, Regulation und Funktion der Sekretase BACE2 in vaskulären glatten 
Muskelzellen in vitro. Zusätzlich wurde die Funktion von BACE2 in einem Modell für 
Atherosklerose, der ApoE-/- defizienten Maus, in vivo analysiert. 
In der vorliegenden Arbeit wird zum ersten Mal gezeigt, dass BACE2 in menschlichen 
vaskulären glatten Muskelzellen exprimiert wird. Mit Hilfe der Immunofluoreszenzanalyse 
konnte bestimmt werden, dass BACE2 sowohl in den Caveolae, im Trans-Golgi Netzwerk 
und in den Endosomen vaskulärer glatter Muskelzellen lokalisiert ist. Außerdem konnte, nach 
Stimulation mit Wachstumsfaktoren, ein schneller Proteasom-abhängiger Abbau des Proteins 
BACE2 festgestellt werden. Die Überexpression von BACE2 in vaskulären glatten 
Muskelzellen führte zur Hemmung der Zellvermehrung. Zusätzlich führte dies zu einer 
Herunterregulierung von c-jun und IκBα-abhängigen entzündungsfördernden Signalwegen. 
Die Herunterregulierung der BACE2 Genexpression durch eine siRNA Transfektion 
resultierte in einer erhöhten Zellvermehrung desselben Zelltyps. 
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Um die Funktion von BACE2 in vivo zu untersuchen, wurden ApoE-/- BACE2 transgene 
Mäuse (BACE2-Tg) generiert und mit ApoE-defizienten Mäusen gekreuzt. In den ApoE-/- 
BACE2-Tg Mäusen konnte, im Vergleich zu den ApoE-/- Kontrollmäusen, eine Reduktion der 
atherosklerotischen Plaques festgestellt werden. Darüber hinaus war die Konzentration von 
entzündungsfördernden Zytokinen wie auch die Konzentration von Cholesterin und Fette im 
Blutplasma verringert. Die vorliegenden Ergebnisse deuten darauf hin, dass BACE2 anti-
proliferative und anti-inflammatorische Eigenschaften in Bezug auf Atherosklerose aufweist. 
Spezifische Induktion und Aktivierung von BACE2 könnte ein neuer therapeutischer Ansatz 
zur Behandlung atherosklerotischer Erkrankungen sein. 
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1. INTRODUCTION 
 
1.1 The Cardiovascular System 
 
Heart, blood vessels and blood constitute the cardiovascular system. The human 
cardiovascular system consists of two blood circulation loops as schematically summarized in 
Figure 1.  
Lungs
Aorta 
Arteries
Pulmonary
circulation
Systemic
circulation
Left atrium
Left ventricle
Right atrium
Right ventricle
Veins
Periphery 
 
 
Figure 1: The human cardiovascular system. The human cardiovascular system consists of a 
pulmonary and a systemic circulation. The pulmonary circulation is a loop between the heart and the 
lungs and is important for the oxygenation of the blood. The systemic circulation provides the 
oxygenized blood (represented by the red arrows) to the periphery of the body. Red areas represent 
the heart.  
 
The human heart is one of the most important organs and is composed of four chambers: two 
muscular atria and two ventricles. The blood flows from the right atrium into the right 
ventricle passing through the tricuspid valve, which allows the blood to flow only in one 
direction. From this ventricle the blood is then pumped to the lungs (pulmonary circulation) 
and returns into the left atrium via the pulmonary vein. Through the bicuspid valve, the blood 
flows into the left ventricle, from which it is driven through the aorta to the periphery of the 
body (systemic circulation). Between the left ventricle and the aorta, the aortic valve prevents 
flow back of the blood into the heart 1, 2. The aorta is anatomically divided into five parts: the 
ascending aorta, the aortic arch, the descending aorta, the thoracic aorta and the abdominal 
aorta. The aorta, the largest artery of the body, is the first vessel in which the blood flows 
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when it is pumped out of the heart to reach all organs and tissues of the body. The blood flows 
through the arteries, the arterioles, the metarterioles and finally reaches the capillary beds. 
The capillary system connects the arterial vascular tree to the venous system and is 
responsible for the exchange of water, gases, nutrients, metabolites and waste between blood 
and tissues. Through venules, small veins and large veins the blood returns into the heart, 
where it is again pumped into the pulmonary circulation for reoxygenation 1, 2.  
The flow of the blood through the body is mediated by the beating of the heart 1. However, 
differences in pressure (pressure gradient) are also important to keep the blood flowing. Blood 
always flows from high to low pressure 1. Blood pressure (BP), which is the force produced 
by the blood flow on the vessel wall, is determined mainly by the cardiac output (CO) and the 
peripheral vascular resistance (PVR): BP= CO x PVR 3. The peripheral resistance mainly 
depends on the blood viscosity, the length of the vessel and the vessel diameter 1.  
The cardiovascular system is a complex constellation of blood pressure, blood distribution 
and transport of several vital elements. In the Western world the cardiovascular system seems 
to be one of the most vulnerable part of the body 4. This is shown by the fact that today 
diseases affecting the cardiovascular system account for 30% of worldwide deaths 4.  
 
1.1.1 Function of the Blood 
 
The function of the blood is to transmit signals (hormones), transport gases (including O2 and 
CO2), nutrients, vitamins, cholesterol, metabolites, and defend the body from microorganisms, 
viruses, foreign proteins, parasites, fungi and cancer (immune system).  
In order to accomplish this role different types of blood cells are involved. Blood cells arise 
from a pluripotent hematopoietic stem cell, through a process called hematopoiesis. In adults 
the bone marrow is the major hematopoietic organ 5. Hematopoietic stem cells can produce 
either lymphoid progenitor cells or myeloid stem cells. The lymphoid progenitor cells 
generate B, T and natural killer cells. These cells are mainly involved in the specific adapted 
immune system. Myeloid stem cells, on the contrary, give rise to white blood cells such as 
neutrophils, eosinophils, basophils, monocytes and mast cells, which participate to the 
nonspecific innate immune system. Additionally, myeloid stem cells also produce red blood 
cells (erythrocytes), which are responsible for the transport of gases and platelets, needed for 
blood homeostasis 6.  
All these cells may produce biologically active molecules, such as cytokines and growth 
factors, which regulate hematopoiesis and inflammatory responses 6. 
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1.1.2 Arterial Structure  
 
The anatomy and structure of an artery depends on its function, size and position within the 
body. Elastic arteries are located close to the heart and are of a large diameter (in humans: 1 to 
2.5 cm). This type of artery is composed of elastic tissues and therefore rhythmically expands 
and recoils helping the blood to move onward. Examples of elastic arteries are the aorta and 
its branches such as the carotid artery, the subclavia and the renal artery 1, 7.  
Muscular arteries are located in the periphery (with exception of the coronary arteries) and are 
thinner (in humans: 0.3 to 1 cm) and more muscular compared with elastic arteries. The wall 
of muscular arteries consists of a thick layer of vascular smooth muscle cells (VSMCs), which 
shows an active role in vasoconstriction (decrease of lumen diameter) and vasodilation 
(increase of lumen diameter) to regulate blood flow and blood pressure 1, 7. 
Histologically, the arterial wall is a well-structured tissue, which consists of three distinct 
layers: the tunica intima, the tunica media and the tunica adventitia (Figure 2) 7. The 
thickness of these three layers varies depending on the type of vessel 8-11. 
 
 
Adventitia
Media
Intima
Endothelial 
cell layerSubendothelium Interna elasticlamina
VSMCs Elastic 
laminae  
 
Figure 2: Structure of an artery. An artery consists of three morphologically distinct layers: The 
tunica intima, the tunica media and the tunica adventitia. The tunica intima consists of a single layer of 
endothelial cells and a subendothelial space. An interna elastic lamina provides flexibility and 
separates the intima from the media. The tunica media is composed of VSMCs bounded by elastic 
laminae. The tunica adventitia, the outer layer, consists mainly of extracellular matrix and collagen 
fibers. 
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The tunica intima is the most internal layer of an artery and it is composed of a single layer of 
endothelial cells, the subendothelium and the internal elastic lamina, which provides 
flexibility, stability and separates the intima from the media. The subendothelium is 
composed of proteoglycans and bundles of collagen (primarily of type I and III) and provides 
mechanical support to the artery. In the subendothelium VSMCs may be present 7, 9.  
The media is the middle layer of the arterial wall and consists predominantly of contractile 
VSMCs bounded by elastic laminae. VSMCs are embedded in collagen and elastin fibers 
(primarily of type I and III) 7.  
The tunica adventitia is the outer layer of an artery and consists of extracellular matrix and 
collagen fibers (primarily of type I), where fibroblasts, mast cells and perivascular nerves are 
embedded. The main function of the adventitia is to provide stability and strength to the 
arterial wall 7. In the adventitia of big arteries blood vessels are found, called vasa vasorum, to 
supply nutrients to the artery 12. 
 
1.1.3 Cells of the Arterial Wall  
 
1.1.3.1 Endothelial Cells  
 
Endothelial cells, which are mounted on a basement membrane (basal lamina) are in direct 
contact with the blood and act as a selectively permeable barrier between the blood and the 
tissues. The endothelium regulates the exchange of water and solutes, and controls the traffic 
of macromolecules, such as lipoproteins. Through the expression of adhesion molecules 
endothelial cells are also responsible of controlling the adhesion, rolling and extravasation of 
inflammatory cells, such as macrophages and lymphocytes, through the endothelial layer. 
This is highly important during inflammatory responses, to allow the influx of cells of the 
immune system from the blood (at the level of the capillaries) into the tissue where infection 
is taking place 6. 
Another important function of endothelial cells is the regulation of vascular tone via different 
effector molecules, which modulate VSMCs contraction and relaxation 13, 14. Nitric oxide 15 
and prostaglandin I2 16 for example are released by endothelial cells and act on adjacent 
VSMCs to induce relaxation, whereas vasoactive factors such as endothelin 17 and 
prostaglandin F2alpha 18 induces VSMCs contractions. 
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Endothelial cells are also involved in the regulation of coagulation, participating in blood 
homeostasis and assuring wound healing. Dysfunction of endothelial cells may lead to 
diseases such as atherosclerosis 13, 19, 20.   
 
1.1.3.2 Vascular Smooth Muscle Cells 
 
VSMCs are multifunctional cells with remarkable plasticity. In healthy condition VSMCs are 
located in the medial layer of the arterial wall and show a quiescent phenotype. The main 
function of VSMCs is the regulation of vascular tone via contraction and relaxation in 
response to various endothelium- or locally-derived substances 13, 16, 21, 22. Through 
contraction and relaxation of VSMCs, arteries change their diameter to regulate blood flow 
and blood pressure 13. This process is important for regulating vascular tone 1. Medial VSMCs 
express contractile proteins, receptors, ion-channels and signal-transducing molecules which 
allow these cells to accomplish their specialized contractile function 13, 21. Among others, the 
expression of contractile proteins such as smooth muscle 22 alpha, calponin, α- and γ-smooth 
muscle actins, smooth muscle myosin heavy chain and polyubiquitin are of crucial 
importance 23.  
VSMCs are also capable of profound reversible changes in response to environmental 
alterations 21. The most evident example of VSMCs plasticity is observed during vascular 
development, vascular injury and in vascular diseases like atherosclerosis and hypertension 24. 
During vascular development VSMCs play a central role in formation of a new vessel wall. 
To accomplish this role the cells have to proliferate at a high rate, migrate and produce high 
amount of extracellular matrix components such as collagen, elastin and proteoglycans. In 
response to vascular injury and diseases VSMCs show a similar phenotype. However, the 
most profound switch in phenotype can be observed in atherosclerosis 24, 25. During 
Atherosclerosis these cells dedifferentiate and migrate to the intima, where they proliferate at 
a higher rate and produce huge amounts of extracellular matrix, cytokines and proteases 26 
(Figure 3). 
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Figure 3: Phenotypic switching of VSMCs during atherogenesis. This figure summarize the 
different phenotypes and characteristics between a quiescent and differentiated VSMC present in the 
media (left) and a dedifferentiated highly proliferative intimal VSMC present in atherosclerotic lesions 
(right).  
 
1.2 Cardiovascular Disease and Atherosclerosis 
 
Diseases causing a detrimental effect to the cardiovascular system are the leading cause of 
death in Western countries 4. Currently, every year more than 17 million people die from 
direct or indirect consequences of cardiovascular diseases worldwide. This represents 30% of 
total deaths 4.  
Cardiovascular diseases include coronary artery disease (leading to heart attack), peripheral 
artery disease, cerebrovascular disease (leading to ischemic stroke), heart failure, 
hypertension, rheumatic and congenital heart disease 2, 4, 27. The most common cardiovascular 
disease is atherosclerosis 2, 27. Atherosclerosis is a multifactorial, systemic, progressive, 
chronic, inflammatory disorder of the arterial wall of medium-size and large arteries, 
characterized by the accumulation of fatty deposits in the inner layer of the arterial wall (the 
tunica intima) 19. Atherosclerosis may cause narrowing and loss of flexibility of the arterial 
wall and, in some cases, the sudden rupture of an atherosclerotic plaque and subsequent 
thrombosis may lead to the total occlusion of the lumen 19, 28-30. Rupture of vulnerable plaques 
represents the leading cause of myocardial infarction (75%) 31 and of ischemic stroke (90%) 
32. 
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1.2.1 Risk Factors of Atherosclerosis  
 
Several risk factors contribute to the development and progression of atherosclerosis and 
cardiovascular diseases in general; some can be controlled or treated, others not.  
 
1.2.1.1 Controllable/Treatable Risk Factors  
 
Among risk factors which may be controlled is hypercholesterolemia, which is manifested by 
an elevated plasma level of low density lipoprotein (LDL) and a reduced level of high density 
lipoprotein (HDL). This represents the most critical risk factor for the initiation and 
progression of atherosclerosis 28. However, severe genetic anomalies affecting the lipoprotein 
metabolism such as mutations in the LDL receptor gene or in the ApoE gene, are known to 
induce high level of hypercholesterolemia which may not be sufficiently controlled and 
treated 33, 34. 
Another important risk factor for the development of cardiovascular diseases, which may be 
easily controlled, is smoking. Smokers have in fact two to four times higher risk for coronary 
heart diseases compared with nonsmokers 35. Hypertension 3, 36, dyslipidemia 37, diabetes 
mellitus 38 and insulin resistance 39 are also known to increase the risk for stroke, heart attack 
and kidney failure. Additionally, sedentary life style 40 and excessive intake of fat 41 may also 
negatively modulate the course of the disease. Overweight and obese people have in fact a 
higher risk for cardiovascular diseases compared to lean persons 42.  
Prevention is an important step in order to inhibit atherosclerotic plaque development. A very 
efficient prevention step is the change of lifestyle by stopping to smoke, dietary interventions 
or physical activities. Additionally, LDL and blood pressure lowering agents, and anti-
thrombotic drugs can also help to reduce the risk for atherosclerosis or even promote its 
regression 43, 44.  
Since the risk factors for atherosclerosis are widely prevalent in our society, the disease has 
been one of the main health problem worldwide for a long time 4. 
 
1.2.1.2 Uncontrollable Risk Factors  
 
Aging is the most important risk factor which can not be controlled. The early stage of 
atherosclerosis, which is the formation of so called fatty streak, may already begin during 
fetal development and during infancy 45. During aging complex metabolic changes occur 
contributing to the progression and complexity of the disease 46. 
1. INTRODUCTION   
 16
Interestingly, the incidence of cardiovascular diseases is higher in men than in women 47, 48. 
Accordingly, estrogen deprivation such as menopause has been shown to be an important risk 
for cardiovascular diseases 47, 48. 
Genetic components also play a major role in the onset and progression of the disease 49. The 
risks are often hereditary, and therefore family history may significantly influence its 
development 28. The investigation of genes that influence the development of atherosclerosis 
have been studied by several groups and is still an intensive field of research 49. Genetic 
variations such as mutations and polymorphisms may define genetic susceptibility and 
profoundly affect the onset and severity of the disease 50. For instance, genetic variants of the 
lipoprotein lipase gene have been associated with dyslipidemia 51 , a polymorphism in the red 
cell Na and K transport gene with hypertension 52 and a polymorphism of angiotensin I-
converting enzyme gene with hypertension and insulin metabolism 53, 54. 
 
1.2.2 Pathogenesis of Atherosclerosis  
 
The course of human atherosclerotic lesion development has been classified by the American 
Heart Association on the basis of histological changes in six consecutive lesion types (Type I-
VI). A schematically representation is shown in Figure 4: 
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Figure 4: Representation of consecutive changes in development of human atherosclerotic lesions as 
classified in lesion types I to VI by the American Heart Association.   
In Column A, the characteristics of the lesion types are listed. In B, a flow chart showing the sequence 
of lesion progression is shown. Type II and III lesions are still reversible as indicated by the double-
headed arrow. Types V and VI lesions are connected by a loop to depict the increase of lesions 
thickness when thrombotic events occur. In C, the mechanisms of lesion growth, in E the period of life 
in which the lesions occur, and in E the clinical correlation are listed.  Adapted from 55. 
 
In 2000 Type VII and VIII lesions are added to the list in order to distinguish lesions which 
develop from Type IV to VI lesions as a result of regression or change of lipids in the 
atherosclerotic lesion 56. Type VII lesions are characterized by calcification, whereas type 
VIII lesions by fibrous tissue changes 56. 
In the following the cellular and molecular changes occurring during atherosclerosis 
development are described and correlated to the histological AHA lesion classification. 
 
1.2.2.1 Endothelial Dysfunction (Lesion type I to III) 
 
The first and crucial event for the initial development of an atherosclerotic lesion is 
endothelial cell dysfunction 19. High plasma lipid concentration is considered to be a key 
factor inducing endothelial dysfunction 19, 26. Endothelial cell dysfunction is characterized by 
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functional changes such as abnormal vascular reactivity, an increased permeability of the 
endothelial layer for LDL, an increased adhesiveness for macrophages and platelets, and 
production of vasoactive molecules such as cytokines and growth factors 19. While LDL 
particles present in the plasma are protected from modification, LDL internalized in the 
subendothelial space may undergo oxidative modification and become more atherogenic 57. 
The accumulation of LDL particles in the arterial wall induces endothelial cells to express 
high amounts of cell adhesion molecules, chemotactic proteins and growth factors, which 
favor the adhesion and migration of leukocytes and monocytes into the subendothelium 10, 28 
(Figure 5). P- and E-selectins, the intracellular adhesion molecule-1 (ICAM-1) and the 
vascular adhesion molecule (VCAM) are of high importance for adhesion, rolling and 
extravasation of monocytes and lymphocytes through the vascular wall 58, 59. 
Chemotactic molecules such as monocyte chemotactic protein 1 (MCP-1) and growth factors 
such as macrophage colony-stimulating factor (M-CSF) recruit monocytes into the vessel wall 
and have a crucial role in stimulating the differentiation of monocytes in macrophages and the 
proliferation of these cells 10, 28.  
 
1.2.2.2 Fatty Streak Formation (Lesion type II) 
 
Monocytes which enter the arterial wall differentiate into macrophages and engulf LDL 
particles leading to the formation of foam cells 10 (Figure 5). Foam cells are efficient 
secretory cells that can produce a number of pro-inflammatory cytokines and growth factors 
amplifying the local inflammatory response in the lesion 60. Interaction of macrophages, foam 
cells and activated lymphocytes establish a chronic inflammatory state characterized by the 
release of high amount of cytokines 28. Foam cells, macrophages, lymphocytes and 
accumulated LDL molecules contribute to the formation of a fatty-streak, which is the early 
stage of an atherosclerotic complex lesion. Fatty-streak provokes the thickening of the arterial 
wall, which is a typical process in atherosclerosis development 19. At this stage of the disease, 
fatty streaks are known to be still reversible 61, 62. 
 
1.2.2.3 Intermediate and Atheroma Lesion Formation (Lesion type III and IV) 
 
As the atherosclerotic process advances lesions become more complex and irreversible 28. 
Cytokines and growth factors present in the local environment of the plaque contribute to the 
phenotypic switching of medial VSMCs 25, 63. During atherosclerosis VSMCs loose their 
quiescent and contractile phenotype resulting in dedifferentiation and migration from the 
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media into the intimal space where the cells proliferate and secrete high amounts of growth 
factors and cytokines 25, 63 (Figure 5). These activated VSMC may take up modified 
lipoproteins (contributing to foam cell accumulation) and synthesize extracellular matrix 
proteins resulting in fibrous cap formation 19, 64. 
Cytokines expressed by VSMCs promote chronic inflammation and progression of 
atherosclerotic lesions by activating leukocytes, promoting endothelial dysfunction and 
proliferation of the cells present in the plaque 65. The transition from a simple fatty streak to a 
much more complex lesion which invades the lumen of an artery is characterized by a 
growing mass of VSMCs and VSMCs-derived extracellular matrix 10. The higher proliferation 
rate of VSMCs in the intimal layer and the huge production of extracellular matrix are 
promoted by cytokines and growth factors secreted by macrophages and lymphocytes 10. 
Contractile VSMCs present in the media mainly produce type I and type III fibrillar collagen; 
on the contrary, intimal VSMCs present in atherosclerotic lesions, mostly secrete 
proteoglycans and fibronectin. This change in local environment is known to alter the 
proliferation rate of surrounding cells 66. 
Lipid-laden cells (macrophages and VSMCs) together with accumulated lymphocytes, cell 
debris, VSMCs, and VSMCs-produced extracellular matrix, are responsible for the formation 
of an advanced atherosclerotic lesion 19 (Figure 5). In addition, this phase of lesion 
development is characterized by interactions between monocyte/macrophages and T cells. 
The complex crosstalk of inflammatory and vascular cells is reflected by a broad range of 
cellular and humoral responses resulting in a chronic inflammatory state within the lesion. 
Activated T cells within the lesion express Th1 and Th2 cytokines 67, 68, whereas activated 
macrophages and endothelial cells express MHC class II molecules and numerous 
inflammatory cytokines, such as TNFα, IL-6, and MCP-1 28. Histologically Type IV lesion 
are usually composed of a lipid-rich core, separated from the vessel lumen by an intact fibrous 
cap covered by endothelium.  
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Figure 5: Schematic representation of the different stages involved in atherosclerosis 
development. Endothelial dysfunction is associated with accumulation of LDL molecules in the 
subendothelium, where an inflammatory response is triggered, thereby promoting adhesion and 
migration of lymphocytes and monocytes into the subendothelium. Macrophages, which differentiate 
from monocytes, accumulate in the arterial wall and internalize LDL, and are thereby transformed in 
foam cells. These cells produce high amounts of cytokines and growth factors contributing to the 
phenotypic switching of VSMCs. Dedifferentiated VSMCs migrate from the media to the intima, where 
they proliferate and secrete high amounts of extracellular matrix. Accumulated VSMCs, VSMCs-
derived extracellular matrix together with foam cells, macrophages and lymphocytes, result in the 
formation of a complex atherosclerotic plaque. 
 
 
1.2.2.4 Fibroatheroma Lesion (Lesion type V) and Vulnerable Plaque 
 
Type V lesions are characterized by formation of prominent new fibrous connective tissue 
leading to narrowing of the arteries. The new tissue consists of collagen and proliferating 
smooth muscle cells. The fibrous cap of an advanced atherosclerotic lesion may become 
thinner, unstable and brake. This process is promoted on a molecular level by cytokines, such 
as interferon-γ (IFN-γ) produced by the cells present in the fibrous plaque. Subsequently, 
macrophages and VSMCs may undergo apoptosis (programmed cell death), resulting in the 
formation of a necrotic core (lipid-rich core) surrounded by a fibrous cap 29, 56. Thinning of 
the fibrous cap is known to be influenced by matrix metalloproteases secreted by 
macrophages and VSMCs. These enzymes in fact degrade extracellular matrix proteins 
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rendering the cap unstable 29, 60. The atherosclerotic lesion is considered as a vulnerable 
plaque when a big necrotic core and only very thin fibrous cap is remaining 19, 56. 
 
1.2.2.5 Complicated Lesion (Lesion type VI ) and Plaque Rupture  
 
Type IV and type V lesions in which the fibrous cap is disrupted (Plaque rupture) resulting in 
hematoma or hemorrhage have been classified in type VI lesions. In these plaques thrombotic 
events occurred. After rupture the high thrombotic lipid core is exposed to the blood, causing 
platelet aggregation and, in most cases, leading to thrombosis, embolization, and vascular 
occlusion (Figure 6). Plaque rupture may result in acute cardiovascular events, such as 
myocardial infarction and stroke. Fortunately, certain plaques exist which remain stable 
during the whole life span 29.  
 
 
Necrotic core Fibrous-cap
Thrombus
Fibrous-capNecrotic coreMacrophages
accumulation  
 
Figure 6: Vulnerable plaque and plaque rupture in atherosclerosis. Left panel: Schematic 
representation of an advanced atherosclerotic plaque composed by a necrotic core surrounded by a 
thin fibrous cap. Right panel: Cross section through a coronary artery. Rupture of the fibrous cap may 
lead to thrombosis, resulting in the occlusion of the arterial lumen. 
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1.2.3 Inflammation and Atherosclerosis  
 
Atherosclerosis is a chronic, inflammatory disease characterized by the presence of 
inflammatory cells such as lymphocytes and macrophages in the atherosclerotic lesion 60. In a 
healthy condition the endothelium does not permit binding and internalization of these 
inflammatory cells into the arterial wall. However, after endothelial dysfunction, endothelial 
cells express adhesion molecules and chemoattractant proteins which promote the recruitment 
of leukocytes and monocytes into the arterial wall 19, 60. The inflammatory process is further 
amplified and regulated by inflammatory cytokines, small signaling molecules produced by 
white blood cells 6. During atherogenesis VSMCs and endothelial cells, which in a normal 
condition do not produce cytokines, also contribute to chronic inflammation of the arterial 
wall by secreting pro-inflammatory mediators 19, 69. 
Cytokines regulate and mediate immune response, inflammation and hematopoiesis and act 
through binding to specific membrane receptors expressed on neighboring cells (paracrine 
action) or on the cell of their origin (autocrine action). The activated receptors transmit the 
information into the nucleus via second messengers (often tyrosine kinases) modulating gene 
expression profile of the cell 6. Activator protein-1 (AP-1) and nuclear factor-κB (NF-κB) 
transcription factors have been shown to be downstream targets of many pro-inflammatory 
cytokines during atherosclerosis 25, 70-72 and to be associated with phenotype switching and 
subsequent proliferation of intimal VSMCs 25, 69, 73. Responses to cytokines include secretion 
of effector molecules, secretion of other cytokines, increased or decreased expression of 
membrane proteins (including cytokine receptors), proliferation and migration (Figure 7) 6.  
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Figure 7: Cytokine signaling pathways. Binding of a cytokine to its receptor results in intracellular 
activation of different kinase cascades, which regulate the activation of transcription factors such as 
AP-1 and NF-κB. Activated transcription factors enter the nucleus resulting in the transcription of pro-
inflammatory cytokines, cytokine receptors, pro-inflammatory molecules and mitogenic factors. Akt: 
protein kinase B; AP-1: Activator protein-1; c-jun: Jun oncogene; ERK1/2: Extracellular signal-
regulated kinases; IκBα: IκB kinase α; JNK: c-Jun N-terminal kinases; MAPK: Mitogen-activated 
protein kinases; NF-κB: Nuclear factor κB; p38: P38 mitogen-activated protein kinase; PI3K: 
Phosphoinositide-3 kinase. 
 
Activation of the dimeric transcription factor AP-1, of which the jun oncogene (c-Jun) is a 
component, occurs by serine phosphorylation 74. To activate NF-κB, on the contrary, the 
degradation of its inhibitor, the IκB kinase α (IκBα), is necessary. In the cytoplasm NF-κB is 
bound to its inhibitor preventing NF-κB from entering into the nucleus. Serine 
phosphorylation of IκBα results in ubiquitinilation followed by degradation allowing NF-κB 
to translocate into the nucleus to activate transcription of target genes 75. 
Activation of both AP-1 and NF-κB is mediated by different kinase-dependent signaling 
pathways. Among others, the phosphoinositide-3 kinase (PI3K)-protein kinase B (Akt)-
pathway was shown to be regulated by cytokines leading to the activation of NF-κB 76. 
Cytokines also lead to the activation of mitogen-activated protein kinases (MAPK), including 
c-Jun N-terminal kinases (JNK) 77, extracellular signal-regulated kinases (ERK1/2) 77 and p38 
kinase (p38) 78, resulting in the activation of both transcription factors 79-82 (Figure 7). 
Activation of AP-1 and NF-κB transcription factors and their entry into the nucleus result in 
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the transcription of genes coding for pro-inflammatory and pro-proliferative molecules, which 
promote and amplify local inflammation in the lesion 82.  
During the atherogenic process cytokines are produced in high amounts by different cell types 
present in the lesion, resulting in a local inflammatory response and VSMC phenotype 
switching 19. The inflammatory activation in the vascular wall is not only promoting the 
initiation of atherosclerotic plaque development, but also contributes to complex and clinical 
risk such as plaque rupture and consequent thrombotic complications 60.  
The most important cytokines produced by intimal VSMCs are platelet derived growth factor 
(PDGF), transforming growth factor β (TGF-β), macrophage migration inhibitory factor 
(MIF), IFN-γ, MCP-1 and interleukin-1 (IL-1) 63, 65. The activated lymphocytes and 
macrophages which accumulate in the arterial wall are known to release cytokines such as 
IFN-γ, IL-1, IL-6 and tumor necrosis factor-α (TNF-α) 28. Finally, foam cells produce 
cytokines and growth factors such as IL-1, TNF-α, PDGF and basic fibroblast growth factor 
(bFGF) 60. Together these cells are responsible for the amplification of the local inflammatory 
response in the lesion and the progression of the disease. Migration and proliferation of 
VSMCs in the arterial wall is for instance known to be stimulated by cytokines such as IFN-γ 
83, IL-1 84, IL-6 85, MIF 86 and TNF-α 87, whereas synthesis of matrix proteins is highly 
promoted by IFN-γ 88, IL-1 84 and MIF 86. IFN-γ also induces VSMCs and macrophages to 
undergo programmed cell death (apoptosis) 56. Anti-inflammatory cytokines are also 
produced, which have the potential of attenuating the immune responses and counter regulate 
atherosclerosis progression. Examples are IL-10, IL-18 and TGF-β which inhibit VSMCs 
proliferation and dedifferentiation 89-91.  
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1.3 Heterogeneity of Atherosclerosis in Humans 
 
Atherosclerosis does not homogenously develop in all arteries of the human body. Generally, 
atherosclerotic plaques occur in medium- and large-sized arteries and mainly develop in 
regions of artery bifurcations and curvatures where the blood shows a complex and irregular 
flow pattern 11. These regions are susceptible towards development of chronic inflammation 
and endothelial cells denote an increased permeability to macromolecules such as LDL, which 
is the crucial event for the initiation of atherosclerosis 10. 
Besides the size of an artery and the differences in blood flow, other aspects seem to play an 
important role. It is in fact well known that within the arterial system, some arteries are more 
protected from atherosclerosis than others 92. The internal mammary artery and the radial 
arteries for examples are highly resistant to the development of atherosclerotic plaques 93-96. 
In contrast, coronary arteries, renal arteries, carotid arteries and the aorta exhibit on the 
contrary a particular predisposition to atherosclerosis development 97.  
This anatomic heterogeneity between different vascular beds suggests that differences in gene 
expression may determine whether an artery is prone or resistant to atherosclerosis 97.  
 
1.4 Experimental Models of Atherosclerosis 
 
1.4.1 Experimental Model of Atherosclerosis in Vitro 
 
Given that VSMCs are critically involved in atherosclerosis development by losing quiescent 
phenotype and migration into the intimal layer of the vascular wall, these cells represent a 
suitable in vitro model for atherosclerosis 25. Techniques to explant VSMCs from human or 
animal vessels are very established and allow studying these primary cells in vitro 98-100. 
Stimulation of VSMCs with mitogenic stimuli is a common method to simulate an 
atherogenic environment 25, 98. The use of VSMCs in vitro is an established procedure and 
may give the possibility to study important molecular aspects of the disease. However, to 
study cellular complexity and chronic aspects, atherosclerosis development has to be analyzed 
in vivo or ex vivo conditions. 
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1.4.2 Experimental Model of Atherosclerosis in Vivo 
 
Knowledge about atherosclerosis development and progression in human ex vivo, stems from 
autopsy studies 101 or, more recently, from intravascular in vivo imaging 31. However, these 
techniques have limitations as only information about the structure but not about the 
properties of atherosclerotic lesions is provided 31, 101. Therefore, the generation of a good 
animal model of atherosclerosis, which mimics human plaque structure and development, is 
very important. Such a model allows better understanding the complexity of this chronic 
disease and, at the same time, provides a tool for the development of therapeutic approaches. 
At the beginning of atherosclerosis research, the disease had been studied mainly in primates 
and rabbits 102. However, these animals have a long gestation time, low number of offspring 
and high costs of maintenance, and are therefore not considered as good animal models 103. 
An excellent mammalian system to study human diseases afflicting the cardiovascular, the 
neuronal, the endocrine and the immune system are mice. Mice have the ability to reproduce 
fast (reproduction time: every nine weeks) and their cost of maintenance is relatively low. 
However, in atherosclerosis research mice show some limitations: in fact, these animals, in 
contrast to humans, have high levels of anti-atherosclerotic high density lipoproteins (HDL, 
> 80 mg/dl) in the blood and low levels of highly atherogenic LDL (< 50 mg/dl) 104. For these 
reasons mice are normally resistant to atherosclerosis. Dietary treatment or/and genetic 
manipulation involved in lipid metabolism are common methods used to attain plaque 
development in these animals. The commonly used mouse models of atherosclerosis and the 
characteristic of each model is listed in (Table 1) 103, 105. 
The most widely used in vivo model of atherosclerosis is the apolipoprotein E-deficient 
(ApoE-/-) mouse. These animals spontaneously develop hypercholesterolemia and develop the 
different lesions-stages observed during atherogenesis in humans 106, 107. In ApoE-/- mice 
atherosclerotic plaques increase and advance to more complex fibrous plaques with age. 
However, these mice do not spontaneously develop plaque rupture 29, 108. 
In ApoE-/- mice, as well as in humans, predilection sites throughout the arterial tree exist, 
which are more susceptible to atherosclerotic lesions formation. The aortic root, the aortic 
arch, thoracic aorta, the brachiocephalic trunk, the pulmonary artery and regions around the 
carotid bifurcation are more susceptible to plaque formation 106, 109, 110. Interestingly, the 
common carotid artery of these mice was shown to be protected from plaque development 111.  
103, 112           106, 107, 113  113, 114      115               103                     116 
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Table 1: Summary of the commonly used mouse models of atherosclerosis.  
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1.5 Candidate Gene Affecting Atherosclerosis  
 
To understand the molecular mechanisms which are involved in complex diseases such as 
atherosclerosis information about changes in gene expression profiles under disease 
conditions is important.  
cDNA microarray technology provide the possibility to identify gene clusters involved in the 
development of the disease based on transcriptional changes 117. In Table 2 different 
microarray approaches using cells, animal or human samples are listed. 
 
 
Cell culture studies 
 
Model Intervention Prominent gene pathways Reference
Murine A404/P19 
smooth muscle 
cells 
Differentiation to smooth 
muscle 
Differentiation, development, chromatin 
remodeling, inhibin βA 
 
118 
Human saphenous 
vein and coronary 
artery endothelial 
cells 
Comparison of baseline 
differences, difference 
with stimulation by 
oxLDL, cytokines 
Regulation of cell growth, oxidoreductase 
activity and stress, immune and anti-
inflammatory responses, fibrinolysis, 
thrombogenesis 
 
97 
Human saphenous 
vein and coronary 
artery SMC 
Comparison of baseline 
differences, difference 
with stimulation by 
oxLDL, growth factors 
α-Chemokines, proinflammatory cytokines, 
apoptosis, inflammation, lipid biosynthesis, 
some β-chemokines, metalloproteinase 
inhibitors 
 
119 
Rat aortic SMC Sodium butyrate 
(antiproliferative agent) 
Cell growth, differentiation, stress 
response, vascular function 
 
120 
Human monocytic 
THP-1 cells 
PMA for differentiation, 
stimulation with oxLDL, 
acLDL, LDL 
Early response genes (transcription 
factors), upregulated early; cell 
proliferation, migration, inflammation, and 
lipid metabolism activated late 
 
121 
 
Animal models 
 
Murine aortic 
tissue 
ApoE-/-, genetic 
background, high-fat diet, 
disease, diet, age 
Inflammatory response, TH1, TH2, wound 
healing, ossification, proteo- and 
peptidolysis, apoptosis, nitric oxide-
mediated signal transduction, cell adhesion 
and migration 
 
 
122 
Murine aortic 
tissue 
ApoE-/-,C57Bl6, genetic 
background 
Growth, differentiation, inflammation, 
catecholamine synthesis, phosphatase 
activity, peroxisome function, IGF activity 
 
123 
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Murine aortic 
tissue 
ApoE-/-,C57Bl6 Lipid and lipoprotein metabolism, defense 
response, inflammation, nuclear 
organization and biogenesis, 
morphogenesis 
 
124 
 
Human tissues 
 
Model Intervention Prominent gene pathways Reference
Human aortas 
(transplant donors) 
Risk factors Prediction gene set for disease severity 
(includes ApoE, osteopontin, lor1, also 
capg, gm2, mmp9, ccrl2) 
 
125 
Human arteries  Risk factors HMG-CoA overexpression in macrophage-
rich lesions 
 
126 
Human arteries Risk factors Known (ApoE, CD68, TIMP, and 
phospholipase D) and unknown genes 
(JAK-1, VEGF receptor-2) 
 
127 
Human coronary 
arteries (explanted 
hearts) 
Risk factors SM dedifferentiation, inflammation  
128 
Human coronary 
atherectomy 
specimens 
Risk factors Inflammation greater in de novo lesions  
129 
Human carotid 
plaques, transplant 
donors (media) 
Risk factors Loss of RGS5 from fibrous cap cells  
130 
Carotid/ mammary 
arteries 
Risk factors Death-associated protein (DAP) kinase  
131 
 
Table 2: Changes in gene expression during atherosclerosis as analyzed by microarray 
technology. Table was modified from 132. 
 
Changes in expression of genes known to be involved in inflammatory pathways are 
frequently detected in the microarrays further confirming the importance of inflammation 
during atherogenesis. Additionally, changes in expression of genes involved in regulation of 
proliferation, differentiation, lipid-metabolism and apoptosis have been identified. As 
microarray studies today cover whole transcriptomes, identification of genes so far unrelated 
to atherogenesis is possible. An example is DAP kinase which was known to be involved in 
apoptosis but not in atherogenesis 131.  
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1.5.1 Identification of a Secretase as a Candidate Gene Protecting From Atherosclerosis 
 
Based on his observation made in the mid-1990s that despite severe hypercholesterolemia the 
common carotid artery of ApoE knockout mice is protected from atherosclerosis compared to 
the thoracic aorta 111, in 2001 Barton and co-workers performed a microarray study 
comparing the gene expression profile of the two different vascular beds. In this study Barton 
et al observed a 3-fold higher expression of β-site APP-cleaving enzyme 2 (BACE2) in the 
atherosclerosis protected carotid artery (Barton M, 2001, unpublished data). This result 
suggested a possible protective role of BACE2 in atherosclerosis and formed the basis of the 
present study.  
BACE2 is a secretase known to be responsible for ectodomain shedding of the amyloid 
precursor protein (APP) and other transmembrane proteins 133, 134. BACE2 is the homologue 
of β-site APP-cleaving enzyme 1 (BACE1). This secretase enzyme is known to cleave APP at 
the β-secretase recognition site, generating a soluble peptide called amyloid β (Aβ), which 
accumulates in the brain causing neurodegeneration in Alzheimer diseased patients 135, 136. 
Even though Alzheimer’s disease and atherosclerosis affect predominantly different organs 
and tissues, the two diseases share similarities. Common risk factors for vascular diseases and 
Alzheimer’s disease are hypercholesterolemia, hypertension, diabetes, estrogen deficiency 
and aging 137. Additionally, inflammation contributes to the pathogenesis of both diseases 19, 
138, and drugs used in patients suffering of atherosclerosis, such as lipid lowering agents, may 
also reduce the incidence of neurodegeneration 139, 140.  
Atherosclerosis and neurodegeneration are often occurring combined and narrowing of the 
cerebral arteries, due to atherosclerosis, is more pronounced in Alzheimer’s disease than in 
nondemented control patients 141.  
 
1.6 Biological Importance of Secretases 
 
Secretases are enzymes which belong to the protease family 142. Proteases catalyze the 
cleavage of peptide bonds by hydrolization. Like all enzymes, proteases bind to their 
substrates only shortly before catalyzing a reaction and releasing the product 143. Proteases 
can be divided in endopeptidases, which cleave internal peptide bonds, and exopeptidases, 
which cleave the terminal peptide bonds. Exopeptidases cleave at the amino 
(aminopeptidases) or at the carboxy (carboxypeptidases) terminus 144. By means of their 
catalytic residues which are essential for their enzymatic activity, proteases can also be 
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classified in 6 groups: Serine proteases, which contain a serine together with a aspartic acid 
and a histidine residue in the active site of the protein (e.g. trypsin, elastase, thrombin), 
threonine proteases, with a threonine residue in the catalytic site (e.g. the proteasome catalytic 
subunits), cysteine proteases, which have a cysteine, a histidine and an aspartic acid as their 
catalytic site (e.g. papain), aspartyl proteaseas, which are enzymes with two aspartic acid 
residues in the catalytic site (e.g. BACE1, BACE2 and pepsin), glutamic acid proteases, 
which have glutamic acid as catalytic active-sites and finally metalloproteases, which have 
glutamic acid, tyrosine and a metal ion (usually zinc) in the catalytic active site [e.g. matrix 
metalloproteases and proteins of the A disintegrin and metalloproteases (ADAM) family] 144.  
Membrane protein proteases, which have the capability of cleaving (shedding) integral 
membrane proteins generating soluble forms, are called secretases (or sheddases). Secretases 
cleave their substrate close to the membrane surface at defined positions of the protein, which 
is determined by secretase specificity and by the topology of the substrate. The determinants 
and factors that result in a transmembrane protein becoming a substrate of secretases is still 
unclear 142. Secretases can only proteolytically cleave type I and type II transmembrane 
proteins which have an accessible cleavage region close to the membrane surface 145.  
The biological function of secretases is highly variable. Depending on the biological context 
and on the transmembrane protein cleaved, proteolysis may have either positive or negative 
physiological outcome. Since secretases are highly specific modulators of different signaling 
pathways involved in many pathophysiological processes such as neurodegeneration, 
apoptosis, oncogenesis and inflammation, these enzymes are considered of high biological 
and therapeutical importance 146. Depending on the substrate cleaved, different biological 
functions are mediated (Figure 8): 
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Figure 8: Biological function of secretases. Representation of different biological outcomes induced 
by secretase-mediated proteolytic cleavage of transmembrane proteins (a-b) and transmembrane 
receptors (c-f). 
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a. Release of Cytokines and Growth Factors in the Extracellular Space or in the Blood 
TNF-α 147 and transforming growth factor α (TGF-α) 148 are examples for proteins synthesized 
as transmembrane precursor, which are released by proteolysis from the cell into the blood or 
into the extracellular space 149 (Figure 8a). Membrane-anchored precursors may be 
biologically active, having the capability of binding to an adjacent receptor in that form 148. 
Additionally, the membrane anchored precursor and the soluble ligand may show different 
receptor specificity and therefore different function 150.  
 
b. Initiation of Intracellular Signaling Pathways via Regulated Intramembrane 
Proteolysis of Transmembrane Proteins 
 In this case the shedded peptide is released into the intracellular space and moves into the 
nucleus to regulate expression of different genes (Figure 8b). This mechanism is for instance 
known during Notch signaling 151. 
 
c. Down-Regulation of Membrane Protein From the Cell Surface 
Proteolysis of transmembrane proteins may serve as post-tranlational modification to rapidly 
downregulate the protein from the cell surface. If the transmembrane protein cleaved by the 
secretase is a transmembrane receptor, cleavage may serve to prevent the signaling cascade 
into the cell (Figure 8c). This process, also called “receptor decapitation”, was observed for 
transferrin receptor 152.  
 
d. Release of Decoy Receptors 
Cleavage of transmembrane receptors may also lead to the secretion of soluble forms. 
Frequently, soluble receptors compete with their membrane-bound counterpart for their 
ligand, and thereby acting as competitive antagonists or “decoy receptors” 146 (Figure 8d). 
The extracellular domain of IL-1 receptor type II (IL-1RII) is for example released by 
metalloproteases. The soluble form competitively binds IL-1, thereby reducing the amount of 
pro-inflammatory cytokines able to bind and activate IL-1 receptor type I (IL-1RI) and 
therefore resulting in inflammation 153.  
 
e. Release of Ligand Stabilizers 
Soluble receptors secreted by proteolysis may also have agonistic function by protecting a 
ligand from degradation/clearance (Figure 8e). Growth hormone binding protein is known to 
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be shedded and to complex as soluble form with growth hormone, resulting in 10-fold lower 
clearance of the ligand 154.  
 
e. Release of Helper Receptors  
A secreted receptor may increase or facilitate the ligand signaling capability into the target 
cell (Figure 8f). The cytokine IL-6 forms a complex with its soluble receptor allowing 
binding to a further signal transducing receptor 155.  
 
As secretases are involved in so many biological contexts, expression, regulation and activity 
of these enzymes need to be tightly regulated and controlled. Regulation of their transcription 
and translation is the first step in controlling secretase expression. Furthermore secretases are 
frequently synthesized as proenzymes (zymogens), which are also preventing an irregular 
activation of these enzymes. Additionally, endogenous inhibitors are important regulatory 
mediators 144. 
 
1.6.1 The Secretase Family  
 
The secretase family consists of α- β- and γ-secretases. These three different types of 
secretases mediate ectodomain shedding of transmembrane proteins at different cleavage 
sites. α- and β-cleavage results in ectodomain shedding and occurs very close to the 
transmembrane domain, whereby α-secretases cleave proteins closer to the plasma membrane 
compared with β-secretases 156, 157. γ-Secretase cleavage results in intramembrane proteolysis 
occurring inside the hydrophobic region of the plasma membrane 158. A number of proteins, 
including TNF-α 147, TGF-α 148, growth hormone binding protein 154 and Notch 151, undergo 
α- β- or γ-secretase-mediated cleavage. However, the most studied transmembrane protein 
shedded by these secretases is APP 157, 159, the key protein involved in senile plaque 
development in the brain of patient suffering from Alzheimer’s disease 135, 136. APP is a 770 
amino acid containing type I transmembrane protein, which is ubiquitinously expressed 
throughout the human body 160. APP is first cleaved by α- or β- secretases resulting in 
ectodomain release (Figure 9). The remaining membrane-bound region undergoes a second γ-
secretase-mediated cleavage resulting in the release of a small extracellular peptide and an 
intracellular C terminal fragment (CTF). Proteolytic cleavage of APP by β-secretase followed 
by γ-secretase cleavage, results in the generation of a neurotoxic peptide called amyoid-β 
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(Aβ) 159. On the contrary, shedding of APP by α-secretase followed by γ-secretase, produces a 
smaller peptide (p3), which is not involved in Alzheimer’s disease 157 (Figure 8). 
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Figure 9: Cleavage sites of α- β- and γ-secretases in the β-amyloid precursor protein (APP). The 
770 amino acid (aa) transmembrane protein APP is schematically represented. The amino acid 
sequence of the region cleaved by the secretases is amplified. The region which represents the highly 
amylogenic peptide Aβ is colored in pink.  
Cleavage of APP by β-secretase followed by γ-secretase results in the release of a 42 amino acids 
Aβ, which is known to accumulate in the brain causing neurodegeneration. α-Secretase cleavage 
prevents the generation of the amylogenic peptide by cleaving APP in the middle of the Aβ domain.  
 
α-Secretase: The transmembrane proteins belonging to the ADAM family are α-secretases 
161. Proteins belonging to this family like TNF-α-converting enzyme (also called ADAM-17) 
162, ADAM-10 163, ADAM-9 164 and ADAM-19 165 are able to cleave APP. BACE2 is 
considered to be an alternative α-secretase 166, 167.  
α-Secretases cleave APP predominantly in the middle of the Aβ domain between lysine 187 
and leucine 188 (K187-L188) 157 , resulting in the generation of a soluble protein (sAPP α) 
and a shorter membrane-bound 83 residues APP C-terminal fragment (APP CTF α) 157. The 
subsequent γ-secretase-mediated cleavage of APP CTF α releases CTFγ in the intracellular 
space and a much shorter (24 amino acids) extracellular peptide called p3, which is non-
amylogenic 157 (Figure 9).  
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β-Secretase: The β-secretase cleavage enzyme 1 (BACE1) has been identified as the major β-
secretase responsible of APP cleavage in vivo 136. BACE1 is a type I transmembrane aspartyl 
protease with two important catalytic active aspartic residues at the N-terminal end of the 
protein. BACE1 is highly expressed in the brain, especially in neurons, and proteolytic 
cleavage of APP by BACE1 followed by γ-secretase cleavage is resulting in the generation of 
neurotoxic Aβ peptide 159. BACE1 cleaves APP predominantly between methionine 671 and 
aspartic acid 672 (M671-D672), generating a soluble protein (sAPP β) and a 99 residues long 
membrane-bound APP CTFβ. APP CTFβ undergoes a subsequent intramembraneous 
cleavage catalyzed by the γ-secretase enzyme, resulting in release of an intracellular fragment 
(CTFγ) and an extracellular 42 amino acid peptide, Aβ, which accumulates in the brain 
leading to neurodegeneration 136 (Figure 9). A different isoform of this secretase, BACE2, 
has also β-secretase cleavage capability. However BACE2 cleaves at this position less 
effectively than BACE1 134. 
 
γ- Secretase: Cleavage of the C-terminal fragment which still remains bound to the 
membrane after α- or β-secretase cleavage is the last step for the generation of the non-
amylogenic p3 or the highly amylogenic Aβ peptide, respectively. This final cleavage is 
accomplished by γ-secretases. These special enzymes are integral membrane proteins with the 
ability to cleave single-pass transmembrane proteins inside the hydrophobic environment of 
the cell membrane. After γ-secretase cleavage of the CTF of APP, the generated small 
peptides p3 or Aβ are secreted from the cell, whereas a CTF γ is released in the intracellular 
space 157 (Figure 9). If the CTF γ has some transcriptional regulatory role, as shown for 
Notch intracellular domain 151, is still unclear. Two homologous proteins, presenilin 1 and 2, 
are responsible for the γ-secretase cleavage of APP 168. 
 
1.6.2 β-site APP-Cleaving Enzyme 2  
 
β-site APP-cleaving enzyme 2 (BACE2, also called Asp1) was cloned in 1999 134, 136, 169, 170 
and was mapped on human chromosome 21q22.3, the Down’s syndrome critical region. The 
gene codes for a 518 amino acid containing type I transmembrane protein with aspartyl 
protease activity. BACE2 is composed of 9 exons, two putative N-glycosylation sites and two 
catalytic aspartic acid residues at exon 2 and 6 respectively 134.  
The N-terminal part of the protein is composed of a small 22 amino acid signal peptide, which 
is important for its trans-membrane localization during protein translation in the 
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endoplasmatic reticulum. The signal peptide is followed by a 40 amino acid pro-peptide 
region, which is proteolitically cleaved in order to generate a mature BACE2 protein 171 
(Figure 10). The pro-peptide of BACE2 was demonstrated to be removed autocatalytically 
166, 172. In neuronal and fibroblast cells BACE2 localizes in the plasma membrane and 
throughout all secretory membrane compartments, including the Golgi apparatus/trans-Golgi 
network (TGN) and early endosomes 166, 171, 172. N-glycosylation and protease activity of 
BACE2 was shown to occur in the acid environment of the Golgi compartment 171, 173. 
 
     
N D D C
SP CPTMProteasePO
Catalytic sites
 
 
Figure 10: Schematic representation of BACE2 domain structure. BACE2 is represented from the 
N- to the C- terminus. Signal peptide- (SP), Pro- (PO), Protease-, Transmembrane- (TM) and 
Cytoplasmic- (CP) domain are represented. The two essential aspartic (D) catalytic residues for the 
secretase activity are indicated.  
 
BACE2 shares 51% homology at the amino acid level with BACE1, showing a particular high 
homology in the catalytic region 134. However, the regulatory domains of the two promoter 
regions do not show high similarity 163, and the promoter activity of BACE2 shows reduced 
function in neuronal cells compared with BACE1 promoter 174. Rather, BACE2 is expressed 
at low level in the brain but is found to be highly expressed in vascularized tissues like liver, 
kidney, pancreas, placenta and heart 134. A role of BACE2 in the pathogenesis of 
inflammatory muscle disease in humans has also been suggested 175. 
BACE2, like its homologue, mediates ectodomain shedding of APP 134. However, this 
secretase cleaves the protein at a different preferential site 166, 167. Whereas BACE1 is the 
main enzyme cleaving APP at the β-secretase site, BACE2 has limited cleavage capability at 
that position but exhibits mainly α-secretase-like activity. BACE2 proteolytically cleaves in 
the middle of the Aβ peptide sequence between phenylalanine 190 and phenylalanine 191 
(F190-F191) efficiently, which is 3 amino acids after the α-secretase cleavage site. For this 
reason BACE2 is also called alternative α-secretase 166, and cleavage of APP by this protein 
followed by γ-secretase proteolysis results, like for the α-secretase cleavage, in a small p3 
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peptide, which precludes the formation and accumulation of Aβ in the brain 167. Furthermore, 
BACE2-transfected cells produce reduced level of Aβ 167, 176, 177 and knock-out of the gene by 
siRNA resulted in elevated secretion of the amylogenic peptide 167, 176. These results strongly 
suggest the limited cleavage capability of BACE2 as a β-secretase and its function in 
precluding the generation of the amylogenic peptide. Thus, BACE1 and BACE2, even being 
highly homologue, have antagonistic effects in the development of Alzheimer’s disease 166, 167, 
177. In order to better understand the biological function of BACE2 in vivo, BACE2 knock-out 
mice were also generated. Interestingly, these mice are fertile, viable and do not show major 
phenotypic abnormality 176.  
Besides APP, IL-1R2, CD16 and TGF-α are also substrates of BACE2 133. Cleavage of IL-
1R2 occurs in a manner similar to APP, resulting in the secretion of IL-1R2 ectodomain and 
the generation of a CTF, which undergoes further γ-secretase proteolysis 133. Functions on cell 
growth or inflammatory pathway mediated by BACE2 have not been described up to now. 
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1.7 Aim of the Project 
 
Based on the identification of BACE2 by microarray in the vascular wall of an 
atherosclerosis-protected artery, this study investigated the potential role BACE2 as a novel 
modulator of human vascular smooth muscle cell (VSMC) function in vitro and 
atherosclerosis in vivo. 
 
Specifically, the aim of the present study was: 
 
1. to characterize the expression, intracellular localization, and expressional regulation in 
human VSMCs. 
2. to determine potential mechanisms by which BACE2 interferes with human VSMC 
function and growth under stimulated conditions. 
3. to determine the effects of BACE2 overexpression on atherogenesis in vivo. 
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ABSTRACT  
 
Atherosclerosis is a chronic inflammatory disease, which is associated with proliferation of 
vascular smooth muscle cells (VSMCs). β-site APP-cleaving enzyme 2 (BACE2) is an 
aspartyl protease with unknown function. In this study we characterize the expression, 
localization, regulation and function of BACE2 in human VSMCs in vitro and the effect of 
BACE2 on experimental atherosclerosis in vivo. We demonstrate that BACE2 is localized in 
caveolae, membranes of secretory pathway and plasma membrane of VSMCs. Growth factor 
stimulation results in a rapid proteasome-dependent degradation of BACE2. Overexpression 
of BACE2 inhibits cell proliferation, and is accompanied with downregulation of c-jun- and 
IκBα-dependent pro-inflammatory signaling. Furthermore, we generated transgenic ApoE-/- 
mice overexpressing BACE2. In these mice the amount of atherosclerotic plaques and blood 
plasma concentrations of the pro-inflammatory cytokine IL-1β, cholesterol and lipids are 
reduced. These results suggest a protective role of BACE2 in atherosclerosis. 
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INTRODUCTION 
 
Atherosclerosis is a chronic inflammatory vascular disease and the most common cause of 
death in Western countries 1. High plasma level of low density lipoproteins (LDL) is an 
important risk factor contributing to the initiation and progression of the disease 2. 
Atherosclerotic plaques are composed of smooth muscle cells (VSMCs), macrophages, lipids, 
T-cells and fibrous material 3. In the development of atherosclerotic plaques, VSMCs have 
been shown to play a central role, particularly in the initiation of the disease 4. In healthy 
vessels, VSMCs are located in the medial layer of the arterial wall and are fully differentiated, 
showing a quiescent contractile phenotype. In diseased condition, however, these cells 
undergo phenotype switching resulting in dedifferentiation and migration from the medial into 
the intimal layer where the cells proliferate, secrete high amounts of cytokines, accumulate 
and start to synthesize extracellular matrix, resulting in thickening of the arterial intimal layer 
and formation of fibrous caps 5. The underlying mechanisms of phenotype switching in 
VSMCs are complex 6. Proliferation of VSMCs in the arterial wall is known to be stimulated 
by growth factors, cytokines and bioactive peptides 7. Generally, the stimulatory molecules 
bind to cognate receptors from which a variety of kinase-dependent signal cascades are 
initiated: insulin receptor substrate 1 (IRS-1)- phosphoinositide-3 kinase (PI3K)- protein 
kinase B (Akt)- glycogen synthase kinase 3 α/β (GSK3) 8, cAMP response element-binding 
protein (CREB) 9, 70 kDa ribosomal S6 kinase (p70S6 kinase) 10, canonical IκB kinase (IκB) 
11 and mitogen-activated protein kinases (MAPK) 12. Among others, dimeric transcription 
factors such as activator protein-1 (AP-1) 13, of which c-Jun is a component, and nuclear 
factor-κB (NF-κB) 11 are targets of these cascades. These transcription factors have been 
shown to be integrators of inflammatory processes 6, 14, 15, which are associated with 
phenotype switching and subsequent proliferation of arterial VSMCs 6, 7, 16. 
The aspartyl protease BACE2 (β-site APP-cleaving enzyme 2) is an alternative  secretase 
which mediates ectodomain shedding of amyloid-β precursor protein (APP) and of other 
transmembrane proteins 17, 18. Its homologue β-site APP-cleaving enzyme 1 (BACE1), a β-
secretase which is predominantly expressed in neuronal tissues 19, 20, has been demonstrated to 
be the rate limiting enzyme in the formation of the neurotoxic amyloid-β (Aβ) from APP. This 
process is the key event in senile plaque development in brains of patients suffering from 
Alzheimer’s disease 19, 20. Proteolytic cleavage of APP by BACE1 at the β-secretase 
recognition site results in generation of a soluble APP (sAPPβ) and a transmembrane C-
terminal fragment-β (CTFβ). The neurotoxic Aβ fragment is generated during a subsequent 
2. MANUSCRIPT DRAFT   
 57
intramembrane proteolytic step catalyzed by a γ-secretase protease complex. BACE2, 
however, preferentially cleaves APP at alternative -secretase recognition sites 21-23 leading to 
the formation of a smaller APP product called p3, which precludes the formation and 
accumulation of Aβ 21, 22. Moreover, BACE2 is expressed at low level in the brain but is 
found to be highly expressed in vascularized tissues as shown by northern blot analysis 17. In 
previous work in this laboratory Barton and coworkers identified BACE2 to be highly 
expressed in arteries using cDNA microarray technology (M. Barton, unpublished observation 
2001 and manuscript in preparation). Thus, we speculated that BACE2 may have a role in the 
regulation of vascular diseases.  
To assess a potential role of BACE2 in atherosclerosis we investigated the expression, 
localization, regulation and function of BACE2 in vitro in VSMCs and in vivo using a well 
established mouse model of atherosclerosis: the apolipoprotein E-deficient mice (ApoE-/-). 
These hypercholesterolemic animals develop all the different lesions-stages observed during 
atherogenesis in human 14, 24, 25. 
In the present study we show that proliferative stimuli negatively regulate BACE2 gene and 
protein expression in VSMCs. Overexpression of BACE2 resulted in reduced activation and 
expression of pro-inflammatory signal cascades and cell proliferation whereas BACE2 gene 
silencing enhanced cell growth. In addition, we generated ApoE-/- BACE2 transgenic mice 
which, in support to our in vitro data, show reduced amount of aortic atherosclerotic plaques, 
reduced plasma concentration of IL-1β, cholesterol and lipids, suggesting a protective role of 
BACE2 in atherosclerosis. 
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MATERIAL AND METHODS 
 
MATERIAL AND METHODS 
 
Materials:  
If not otherwise stated all chemicals were obtained from Sigma (Aldrich, Deisenhofen, 
Germany). Primers and oligonucleotides were synthesized from Microsynth (Balgach, 
Switzerland). 
 
Site Directed Mutagenesis of BACE2 
A mutant (MUT) BACE2 lacking protease activity was generated by mutating the two 
catalytic aspartic acid residues (D) 23 to alanine (A). The mutations were inserted by site-
directed mutagenesis using pCDNA3.1-wild-type-BACE2 as a template and primers 
containing the mutated sequence (for mutation D110A: forD110A and revD110A primers; for 
mutation D303A: forD303A and revD303A primers, Supplementary Table 1) using a Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer’s 
instruction.  
 
BACE2 Plasmid Construction  
Human wild-type (WT) and mutant (MUT) BACE2 were amplified by PCR using a forward 
primer containing a XbaI restriction site (forXbaI primer, Supplementary Table 1) and a 
reverse primer containing a BamHI restriction site (revBamHI primer, Supplementary Table 
1), using Proof Star DNA Polymerase (Qiagen, Basel, Switzerland) (Q-Solution, 1x Proof 
Star Buffer, 2.5 mmol/l MgSO4 and 10 mmol/l dNTP). After digestion with XbaI and BamHI, 
PCR products were ligated into c-FUW 26, a replication-defective lentivirus vector, using T4 
Ligase (Roche, Rotkreuz, Switzerland). 
The mammalian expression vector pCAG 27 (Supplementary Fig. 1a) was digested with 
EcoRI and treated with alkaline phosphatase, CIAP (Roche, Rotkreuz, Switzerland) to avoid 
religation. An EcoRI-SalI-HindIII-EcoRI-linker oligonucleotide (forLinker and revLinker, 
Supplementary Table 1) was ligated with the linearized expression vector. BACE2 was 
amplified by PCR using a SalI-containing forward primer (forSalI primer, Supplementary 
Table 1) and a HindIII containing reverse primer (revHindIII primer, Supplementary Table 
1) using Proof Star DNA Polymerase (Q-Solution, 10x Proof Star Buffer, 2.5 mmol/l MgSO4 
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and 10 mmol/l dNTP). Amplicons and pCAG were cleaved with SalI and HindIII and ligated 
with T4 DNA Ligase.  
All constructs amplified by PCR were verified by sequencing (Microsynth, Balgach, 
Switzerland). 
 
Cell Culture Procedures 
Human embryonic kidney 293T cells (HEK293T) were maintained in Dulbecco Medium 
(Bioconcept, Allschwil, Switzerland), fetal human aortic smooth muscle cells (FLTRs) in 
DMEM High Glucose (Biochrom AG, Basel, Switzerland) and human vascular smooth 
muscle cells (VSMCs) in DMEM Ham’s F12 medium (Bioconcept, Allschwil, Switzerland) 
supplemented with 10% fetal calf serum (FCS, Sigma Aldrich, Deisenhofen, Germany), 2 
mmol/l glutamine (Biochrom AG, Basel, Switzerland) and 100 μg/ml penicillin/streptomycin 
(Gibco, Basel, Switzerland). 
VSMCs were explanted from human umbilical veins (an arterial vessel) using the explant 
technique as described 28, 29. Human umbilical cords were obtained at the Klinik für 
Geburtshilfe at the Universitätsspital Zürich. The studies were conforming to the principles 
outlined in the Declaration of Helsinki and approved by the Ethics Committee of the 
University Hospital Zurich. Informed consent was obtained from all patients. Explanted cells 
were then cultured in petri dishes and identified by their hill and valley morphology using 
phase-contrast microscopy and immunofluorescence stained for -actin 29. For experiments 
subconfluent cells at passage 3-6 were used. 
Cells were kept at 37°C in a 5% CO2 incubator and passaged with 0.05% trypsin (w/v)/0.02% 
EDTA (w/v) in phosphate-buffered saline (PBS, Gibco, Basel, Switzerland). 
Before experiments cells were starved with 0.1% FCS for 24 h. Stimulation experiments with 
10% fetal calf serum, 20 ng/ml human recombinant platelet-derived growth factor BB 
homodimer (PDGF; Calbiochem, Dietikon, Switzerland) or 50 μg/ml low-density lipoprotein 
(LDL, isolated from human EDTA plasma obtained from healthy blood donors as described 
in 29) were performed when cells were 70% confluent.  
Proteasome inhibitors MG-132 (10 μmol/l, Calbiochem, Dietikon, Switzerland) and 
Lactacystin (20 μmol/l, Alexis Biochemicals, Lausen, Switzerland) were preincubated for 6 h 
before stimulation with FCS. 10 and 100 nM of β-secretase inhibitor (C73H118N16O27, MP 
Biomedicals, Illkirch, France) and γ-secretase inhibitor IX (C23H26F2N2O4, Calbiochem, 
Dietikon, Switzerland) were preincubated for 30 min before FCS treatment. All stimulations 
were terminated by washing cells with ice-cold PBS for further procedures.  
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Cell Proliferation Assay 
Primary VSMCs (50% confluent) were starved for 24 h (0.1% FCS), stimulated by FCS and 
after 18 h (methyl-3H)-thymidine (3 μCi/ml, 1.5 μmol/l) was added (GE-Healthcare, Zurich, 
Switzerland). Thymidine incorporation was measured 6 h later using a β-counter as 
described 30.  
Alternatively, a cell counting method was used. Equal number of cells were plated. The 
following day cells were starved for 3 days followed by 2 days of FCS stimulation. Cells were 
counted using a hemocytometer immediately before starvation, after 3 days of starvation and 
after 2 days of FCS stimulation. 
 
Generation of Smooth Muscle Cells Stably Overexpressing Wild-Type and Mutant 
BACE2  
Stable WT and MUT BACE2 overexpressing VSMCs and FLTRs and CTL cells were 
generated by lentiviral transduction 26. Duplication-deficient lentiviruses were assembled in 
HEK293T cells by transiently tranfecting the cells with the generated c-FUW lentivirus 
constructs [c-FUW(WT BACE2); c-FUW(MUT BACE2) or c-FUW] described above along 
with two virus packaging plasmids (pHCMV-G and pCMV) using Lipofectamine 2000 
(Invitrogen, Basel, Switzerland) in OptiMEM I Reduced Serum Medium (Gibco, Basel, 
Switzerland) according to the manufacturer’s instruction. Cell culture supernatants containing 
the replication-defective lentiviruses were collected 48 h after transfection, centrifuged for 5 
min at 150 g (4°C), filtered (0.45 μm), pipetted onto 70% confluent VSMCs (or FLTR cells) 
and incubated overnight. Next day supernatants were replaced with fresh cell culture medium. 
The virus-transduced cells were expanded and tested for overexpression (Supplementary 
Fig.2). 
 
In Vitro Assay of BACE2 Proteolytic Activity  
The second day after transfection, cells were washed with PBS and lysed in 10 mmol/l Tris 
HCl, pH 7.0 as described 31. Lysates were centrifuged at 15,700 g (4°C) for 15 min and the 
pellet containing membrane bound proteins was resuspended in 25 mmol/l Tris, pH 4.5. After 
passing the membrane proteins for 10 times through a 29 g syringe needle, proteins were 
homogenized for 30 min at 4°C on a rotor. Cell debris was removed by centrifugation at 400 g 
for 10 min and protein concentration was determined in the supernatant using the Bio-Rad 
Protein Assay Kit (Bio-Rad Laboratories, Reinach, Switzerland). 
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An APP-based substrate (Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp, customer-designed by 
Bachem AG, Bubendorf, Switzerland) corresponding to the peptide sequence of the 
alternative α-secretase cleavage site targeted by BACE2 21-23, and containing a fluorescence 
donor and a quencher acceptor at each end was used. The full-length substrate is only weakly 
fluorescent but becomes highly fluorescent after proteolytic cleavage (fluorescence resonance 
energy transfer (FRET)-principle). Activity of the lysates (5 μg) was measured in an in vitro 
assay after addition of 10 μg of the substrate at 37°C and by reading fluorescence at 320 and 
420 nm excitation and emission wavelengths, respectively using Spectra Max M2 microplate 
reader (Bucher Biotec, Lucerne, Switzerland) machine. Background fluorescence was 
subtracted.  
 
RNA Extraction and Quantitative Real-Time PCR  
RNA was isolated following the manufacturer’s instruction (Qiagen, Hilden, Germany).  
Total RNA was extracted using either the RNeasy Micro kit (VSMCs), the RNeasy Micro kit 
for RNA isolation from fibrous tissues (aorta, carotid, heart and muscle), or the RNeasy Mini 
kit for RNA isolation from animal tissues (liver, kidney, brain, lung and spleen). 
Purity of RNA was controlled by RT(−) reactions (PCR with non-transcribed RNA). RNA 
from the different murine tissues was reverse-transcribed with the QuantiTec Reverse 
Transcription kit (Qiagen, Hilden, Germany), whereas RNA extracted from human primary 
cells was reverse-transcribed with the Omniscript RT kit (Qiagen, Hilden, Germany).  
Real-time quantitative PCR was used to determine steady-state mRNA expression using 
human (Supplementary Table 2) or mouse (Supplementary Table 3) primers. Two-step 
PCR was performed with iQ SYBR Supermix PCR kit (Bio-Rad Laboratories, Reinach, 
Switzerland) as follows: activation of the hot start Taq polymerase for 3 min (95°C), followed 
by 40 cycles of denaturation at 95°C for 15 sec (step 1), and annealing and extension at 60°C 
for 1 min (step 2). Fluorescence was detected at the end of each extension step. Identity and 
specificity of amplicons were confirmed by agarose gel electrophoresis, melting curve 
analysis and sequencing. Gene expression was calculated using the 2-ΔCT method 32. The 
relative amount of each mRNA was normalized to the housekeeping gene β-actin.  
 
Protein Extraction and Western Blot 
Cells were placed on ice, washed with ice-cold PBS and proteins were extracted with lysis 
buffer (1% NP-40, 100 mmol/l NaCl, 25 mmol/l β-glycerophosphate, 20 mmol/l Tris HCl pH 
7.5, 1 mmol/l EDTA, 1 mmol/l Na-PPi, 1 mmol/l NaVO3) at 4°C. Extracts were homogenized 
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for 30 min on a rotor at 4°C, followed by centrifugation at 15,700 g (4°C) for 10 min. 
Supernatants were collected and protein concentrations were measured. Equal amounts of 
proteins (20-30 μg total protein) were separated by electrophoresis with 4-12% SDS/PAGE 
gradient gels (Invitrogen, Basel, Switzerland) and blotted onto a nitrocellulose membrane 
(GE-Healthcare, Zurich, Switzerland). The membranes were incubated for 1 h in blocking 
solution (20 mmol/l Tris-HCl pH 7.5, 150 mmol/l NaCl, 0.1% v/v Tween-20, and 1% w/v 
non-fat milk powder) and overnight at 4°C with primary antibodies, diluted 1:1000 or 1:500 
in blocking solution. After washing the membrane with blocking solution, the appropriate 
horseradish peroxidase (HRP)-conjugated anti-rabbit, anti-mouse (GE-Healthcare, Zurich, 
Switzerland) or anti-goat (Santa Cruz Biotechnology, LabForce, Nunningen, Switzerland) 
IgG secondary antibodies were added at dilutions 1:5,000; 1:2,000 or 1:10,000, respectively, 
to the blocking solution for 45 min at room temperature. After washing the membrane with 
blocking solution and Tris buffered saline (TBS), the immunoreactive bands were visualized 
using enhanced chemiluminescence (ECL, GE-Healthcare, Zurich, Switzerland). The 
following primary antibodies were used: goat anti-BACE2, mouse anti-α-tubulin, rabbit anti-
Gαq/11 (Santa Cruz Biotechnology, LabForce, Nunningen, Switzerland), mouse anti-caveolin 1 
(BD Biosciences, Basel, Switzerland), rabbit anti-phospho-(Ser473)-Akt, rabbit anti-phospho-
(Thr202/Tyr204)-ERK1/2 MAPK (Cell Signaling, Boston, USA). 
 
RNA Interference of BACE2 
siRNA Oligonucleotides used in this study are: sense, ACAGAGAGGUCUAGCACAUtt; 
antisense, AUGUGCUAGACCUCUCUGUtt. These oligonucleotides specifically mediated 
degradation of BACE2, but not of BACE1, mRNA 21. Annealed siRNA (25 pmol/ml) was 
diluted in Opti-MEM I Reduced Serum Medium and transfected into VSMCs at 40-50% 
confluency overnight using Lipofectamine 2000 as described in the manufacturer’s 
instructions. As negative control a scramble siRNA (siCONTROL, Dharmacon, Lausanne, 
Switzerland) was used. After transfection the cells were incubated at 37°C (5% CO2) for 24-
94 h prior to testing gene silencing.  
 
Fractionation of Cytosolic and Membrane Proteins 
Cell fractionation was performed as described 33 with minor modifications. The pelleted cells 
were resuspended in buffer containing protease inhibitors (25 mmol/l HEPES, 1 mmol/l 
EDTA, 1 μg/ml leupeptin, 1 μg/ml pepstatin A, 100 μmol/l phenylmethylsulfonylfluoride) 
and passed for homogenization 10 times through a 29g  syringe needle followed by 10 min 
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centrifugation at 100 g (4°C). The supernatant containing total cell lysates was 
ultracentrifuged for 1 h at 55,000 g (4°C). The resulting supernatant was referred to as 
cytoplasmic fraction. For solubilization of membrane proteins the pellet was further 
resuspended in triton X-100 containing buffer (20 mmol/l HEPES, 2 mmol/l EDTA, 50 
mmol/l β-glycerolphosphat, 1 mmol/l dithiothreitol DTT, 1 mmol/l Na3VO3, 1% Triton-X100, 
10% glycerol, 1 μg/ml leupeptin, 1 μg/ml pepstatin A, 100 μmol/l 
phenylmethylsulfonylfluoride) and homogenized as before followed by 1 h ultracentrifugation 
at 55,000 g (4°C). The supernatant was referred to as triton-soluble and the pellet resuspended 
in loading buffer as triton-insoluble membrane fraction.  
 
Immunofluorescence Analysis  
Cells were cultured on sterile coverslips till 70% of confluency was reached. Cells were 
washed with cold PBS and fixed for 10 min in 4% Paraformaldehyde (PFA, Sigma Aldrich, 
Deisenhofen, Germany) at room temperature. Cells were permeabilized for 5 min with 0.05% 
Triton X-100 in PBS (Sigma Aldrich, Deisenhofen, Germany) and washed three times (for 10 
min), respectively, with PBS, 50 mmol/l NH4Cl (in PBS) pH 7.2 and again with PBS. After 
blocking  for 30 min with 5% donkey serum (DS, Jackson ImmunoResearch, West Baltimore, 
USA) coverslips were transferred to a silicon chamber and incubated overnight at 4°C with 
primary antibodies against BACE2 and against cell compartment specific proteins. The 
following day cells were washed with 5% DS followed by TRITC- or Cy5-labelled secondary 
antibody/ies incubation for 1 h at room temperature. All antibodies were diluted 1:100 in 5% 
DS. After washing the cells, slips were mounted onto a microscope slide using Moviol-
solution (Calbiochem, Dietikon, Switzerland). Fluorescence-labeled proteins were visualized 
by confocal microscopy (Leica SP2) at 550 nm-570 nm excitation and emission wavelengths, 
respectively for TRITC and at 650 nm-670 nm for Cy5. Images were processed using Adobe® 
Photoshop®. The following antibodies were used: rabbit anti-BACE2 (Zymed Laboratories, 
San Francisco, USA), mouse anti-Early endosomal antigen 1 (EEA1), mouse anti-CD107a, 
mouse anti-caveolin 1, mouse anti-syntaxin (BD Biosciences, Basel, Switzerland), anti-rabbit 
TRITC and anti-mouse-Cy5 (Jackson ImmunoResearch, West Baltimore, USA).  
 
Flow Cytometry Analysis 
Cells were fixed with 1% PFA for 20 min at room temperature. Cells were permeabilized by 
incubation with 0.05% Triton X-100 in PBS for 10 min to determine total BACE2, or left 
unpermeabilized to identify BACE2 localized on the plasma membrane. After washing with 
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PBS, cells were incubated with an antibody recognizing the N-terminus of BACE2 protein 
(rabbit anti-BACE2; Serotec, Oxford, UK) for 1 h at room temperature. After washing, cells 
were incubated with anti-rabbit FITC-conjugated secondary antibody (Jackson 
ImmunoResearch, West Baltimore, USA) for 30 min at room temperature, fixed again with 
1% PFA for 10 min and analyzed by flow cytometry at 492 nm excitation and 520 nm 
emission (FACSCalibur, BD Biosciences, Basel, Switzerland). Antibodies were diluted 1:100 
in 0.1% Normal Donkey Serum, 0.025% TritonX-100 (for the intracellular BACE2 
localization) or just in 0.1% Normal Donkey Serum (for the plasma membrane BACE2 
localization) in PBS. As a negative control cells were incubated with the fluorescent 
secondary antibody only. 
 
Bio-Plex Assay 
Phosphoprotein Detection: Phosphorylation of 8 different proteins was determined using the 
Bio-PlexTM suspension array system kit (Bio-Rad Laboratories, Reinach, Switzerland). Cells 
were washed and frozen once at -80°C to facilitate cell lysis, resuspended in 150 μl lysis 
buffer (provided in the kit) and protein concentration was determined by the Bradford 
method. 45 μg proteins were used to detect and quantify the phospho-proteins according to 
the manufacturer’s guidelines. Phosphorylation was normalized to protein content. The 
phosphorylation of the following proteins was analyzed: cAMP response element-binding 
protein (CREB Ser133), Insulin receptor substrate 1 (IRS-1 Ser636/Ser639), 70 kDa ribosomal S6 
kinase (p70 S6 Kinase Thr421/Ser424), extracellular signal-regulated kinases (ERK1/2 
Thr202/Tyr204, Thr183/Tyr185), p38 mitogen-activated protein kinase (p38 MAPK Thr180/Tyr182), 
glycogen synthase kinase 3 α/β (GSK-3 α/β Ser21/Ser9), c-jun oncogene (c-jun Ser63) and 
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IκB-α 
Ser32/Ser36). 
Cytokines Detection: IL-1β, IL-6 and TNF-α cytokines levels were quantified in the plasma 
of ApoE-/- and ApoE BACE2-Tg mice was determined using the Bio-PlexTM suspension 
array system kit according to the manufacturer’s guidelines. 
 
Generation of BACE2 Overexpressing Mice and Dietary Treatment 
The studies and animal facilities were approved by the “Kommission für Tierversuche des 
Kantons Zürich” (Switzerland). Housing and experimental procedures were in accordance 
with the Swiss animal protection law. The pCAG_WT BACE2 plasmid containing full length 
sequence of human BACE2 under the control of the CAG promoter was propagated in 
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Escherichia coli DH5α and the minigene was excised with NotI. The fragments were purified 
from a 1% agarose gel with Qiaquick extraction kit (Qiagen, Basel, Switzerland) and 
processed following the manufacturer’s recommendations. The transgenetic techniques were 
performed at the Institute of Laboratory Animal Science of the University of Zurich under 
SPF conditions. Nuclear injections into fertilized C57BL/6J oocytes were carried out by 
conventional methods 34, 35. 
Transgenic founder were identified by PCR using a CAG- promoter specific primer and a 
BACE2- specific primer (CAG and BACE2 primers, Supplementary Table 4). One founder, 
C57BL/6J Tg(cag-AsgN)1372zbz, was identified and crossed with C57BL/6J ApoE-deficient 
mice to generate C57BL/6J ApoE-/- tgBACE2+/- mice. Mice were bred always with C57BL/6J 
mice to exclude positioning effects due to transgene insertion. Genotyping of the mice was 
performed using the same primer combination as for the identification of the founder animals. 
Following primers were used for the ApoE locus: oIMR0180, oIMR0181 and oIMR0182 
(Supplementary Table 4) 36. These primers generate a 155 bp band for the WT locus and a 
245 bp band for the targeted locus. If the animals are heterozygous both products are 
amplified 36. 
Healthy male mice (C57BL/6J ApoE-/- and C57BL/6J ApoE-/- BACE2-Tg) were housed at the 
institutional animal facilities on a 12:12-h light-dark cycle. Animals had free access to food 
and water. In one treatment group mice were fed for 10 weeks with control diet (Kliba Nafag 
3430, Kaiseraugst, Switzerland) whereas in the other treatment group mice were fed with 
standard chow for 10 weeks followed by a high fat/cholesterol diet (Research Diet D12108) 
for 15 weeks. At the end of the treatment, both groups were anesthetized (20 mg/kg body 
weight Xylazine, 100 mg/kg body weight Ketamine and 3.0 mg/kg body weight 
Acepromazine in 0.9% NaCl) and exsanguinated via cardiac puncture. Organs for RNA 
expression were cleaned in RNA-later (Qiagen, Basel, Switzerland) and snap-frozen in liquid 
nitrogen and stored at -80°C. Blood was centrifuged at 5,900 g at 4°C for 15 min and plasma 
was stored at -80°C. 
 
Glucose Tolerance Tests and Lipid Measurements 
In the week of the experiment mice were starved overnight, weighed and fasting glucose 
levels were measured, followed by glucose tolerance test (GTT) as described 37.  
Levels of plasma cholesterol, triglycerides and free fatty acids were determined using 
colorimetric assays (Roche Applied Science). Separation of lipoproteins was performed by 
FPLC as described 38. 
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Quantification of Atherosclerosis 
Mice were sacrificed and the aorta was dissected, cleaned from the perivascular fat under a 
microscope, cut open longitudinally and pinned onto a black-colored silicon plate. The whole 
aorta was fixed in 4% PFA at 4°C overnight followed by oil red O staining overnight. The 
pinned aortas were washed twice and stored in PBS at 4°C. Pictures of stained aortas were 
taken using a Nikon (coolpix 2200) digital camera and atherosclerotic plaques area were 
quantified using the Image J (NIH Image) software program and calculated in percentage of 
total area. 
 
Statistical Analysis 
All statistical analyses were performed using the GraphPad or StatView software. Since the 
data of each experiment were normally distributed (D’Agostino and Pearson omnibus 
normality test), comparisons of group means were performed by two-tailed paired Student’s t-
Test (to compare the means of two matched groups), by two-tailed unpaired Student’s t-Test 
followed by Welch’s correction (to compare the means of two unmatched groups) or by one-
way ANOVA followed by Bonferroni post-hoc test (to compare the means of three or more 
groups). Statistical significance was accepted at P values < 0.05. Data are expressed as 
means±SEM. For time courses, area under the curve (AUC) was calculated using the 
GraphPad software. 
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RESULTS 
 
Characterization of BACE2-Mediated Protease Activity  
BACE2 is a transmembrane protein of 57 kDa, containing a protease domain with two 
catalytic aspartate (D) residues (Fig. 1a). To analyze protease activity of human wild-type 
(WT) and protease-inactivated (D110A and D303A, MUT) BACE2 proteins an in vitro 
fluorescent-based activity assay was performed using lysates from HEK293T cells transiently 
transfected with WT, MUT BACE2 or control vector (CTL) and a FRET-competent substrate 
representing the peptide sequence of the alternative -cleavage site of APP. In lysates of WT 
but not the MUT BACE2 expressing cells an enhanced proteolytic activity was measured 
compared to CTL cells as quantified by integration of cleavage activity over time (area under 
the curve: 2336±541 vs. 818±77.8, P=0.006, Fig. 1b). Similar expression levels of the 
constructs were confirmed by Western blot (Fig. 1c). Only in cells expressing WT BACE2 an 
additional band of 54 kDa was visible (Fig. 1c) indicating that prodomain processing of 
BACE2 is dependent on an intrinsic functional protease domain confirming data suggesting 
an autoproteolytic activation mechanism 22, 39. 
 
Subcellular Localization of BACE2 in Human Vascular Smooth Muscle Cells 
To investigate subcellular distribution of human BACE2, VSMCs were fractionated. 
Endogenous (CTL) and stably overexpressed WT and MUT BACE2 were detected 
exclusively in the triton-insoluble membrane fraction as analyzed by Western blot (Fig. 1d) 
indicating that subcellular distribution is independent of protease activity. Purity of the 
fractions was confirmed with fraction-specific antibodies: α-tubulin for cytoplasmic fraction, 
the small G-protein Gαq/11 for the triton-soluble and caveolin-1 for the triton-insoluble fraction 
(Fig. 1d).  
To further characterize subcellular compartmentalization of endogenous BACE2, cells were 
immunostained for cellular compartment specific marker proteins and for BACE2 followed 
by confocal microscopy (Fig. 1e). BACE2 was partially co-localized with early endosomal 
compartments, caveolae and the trans-Golgi network as visualized in yellow in the merged 
pictures. In the lysosomes no co-localization was detected (Fig. 1e). 
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Downregulation of BACE2 Gene and Protein Expression in VSMCs by Proliferative 
Stimuli 
As expression of regulatory molecules may be affected in proliferating VSMCs during 
atherogenesis 40, the effect of proliferative stimuli on BACE2 gene and protein expression 
levels was investigated in human VSMCs, as an in vitro model of atherogenesis. Exposure of 
VSMCs to PDGF-BB, LDL or FCS downregulated steady-state BACE2 mRNA expression 
levels starting at 3 h with a further decrease till 24 h post stimulation (Fig. 2a, P<0.05 vs. 
CTL). Exposure to FCS for 24 h had the strongest effect resulting in downregulation of 
74.2±2.4% compared to control cells. Similarly, BACE2 protein expression decreased after 
exposure to FCS and PDGF-BB as shown by immunoblot (Fig. 2b). Immunofluorescence 
analysis also revealed a time-dependent decrease of BACE2 protein after FCS stimulation, 
which was already detectable after 5 min (Fig. 2c). These results suggest an inhibitory effect 
of proliferative stimuli such as FCS, LDL and PDGF-BB on BACE2 mRNA and protein 
expression levels. 
As BACE2 is localized in the plasma membrane and in intracellular membranes (39, 41 and 
Fig. 1e), we analyzed whether BACE2 protein expression was differently affected in the 
plasma membrane compared with intracellular compartments after stimulation with FCS. 
BACE2 expression in the plasma membrane (unpermeabilized cells) and total cellular 
expression (permeabilized cells) was quantified by measurement of cellular mean 
fluorescence intensity (MFI) using an antibody against the N-terminal extracellular part of 
BACE2 and flow cytometry. In unstimulated cells, plasma membrane-localized BACE2 was 
5-fold lower compared with total BACE2 protein expression and remained unchanged after 
FCS stimulation (open bars, Fig. 2d, upper left and lower panel). Total amount of BACE2 
protein (black bars) was reduced after 10 min of FCS stimulation (-27±6.5%, P=0.017) and 
further decreased after 30 min of treatment (-47.3±7.6%, P=0.001, Fig. 2d, upper right and 
lower panel). The rapid decrease of BACE2 protein expression observed after FCS 
stimulation suggested rapid degradation via proteasomal pathways 42. To test this hypothesis 
cells were preincubated with 2 different proteasome inhibitors followed by FCS stimulation. 
The FCS-dependent decrease of BACE2 protein amount was abolished in cells preincubated 
with proteasome inhibitors (Fig. 2e) indicating a critical role of the proteasome in BACE2 
protein degradation, a mechanism, which was previously demonstrated for its homologue 
BACE1 43.  
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Crucial Role of Protease Activity of BACE2 on Cell Proliferation  
Since a decrease of BACE2 protein after incubation with proliferative stimuli is accompanied 
with cell proliferation, we tested whether BACE2 has a regulatory role in cell growth. Indeed, 
overexpression of WT BACE2 in VSMCs resulted in significant decrease in cell proliferation 
as measured by [3H]-thymidine incorporation after FCS stimulation compared to control cells 
(-49±8.2%, P=0.0009, Fig. 3a). Overexpression of MUT BACE2 in VSMCs had no effect on 
cell proliferation compared to control cells (92.2±9.3% vs. 100%, n.s, Fig. 3a) indicating that 
the growth inhibitory effect of BACE2 in human VSMCs depends on its intrinsic proteolytic 
activity. This finding was further confirmed in FLTRs cell line in which overexpression of 
WT, but not of MUT BACE2 resulted in decrease of cell proliferation as determined by cell 
counting (-50.3±2.4%, P=0.0005 vs. CTL, Fig. 3b). In order to further confirm the role of 
BACE2 in VSMCs proliferation, endogenous BACE2 gene expression was downregulated 
using gene-specific siRNA oligonucleotides (Supplementary Fig. 3). Cell proliferation in 
BACE2 siRNA-transfected cells was 80±20.5% and 72±20.1% increased after stimulation 
with 2% or 10% FCS compared to control cells, respectively (P=0.042 for 2% FCS and, 
P=0.037 for 10% FCS, Fig. 3c). Similarly, pretreatment of the cells with a β-secretase 
inhibitor, which has been shown to also inhibit BACE2 enyzmatic activity 44, increased FCS-
induced cell proliferation (43±13%, P=0.002, Fig. 3d). Taken together, we could demonstrate 
that an active protease domain of BACE2 is essential to inhibit cell proliferation of smooth 
muscle cells. 
 
No Direct Role of Soluble Fragments Generated by BACE2 in Inhibition of Cell 
Proliferation 
Inhibitory signals can be transmitted via soluble ligands which are synthesized as trans 
membrane precursor proteins and released by proteolysis from the cell into the cell culture 
supernatant 45. To investigate the possible involvement of this mechanism in inhibition of cell 
proliferation by BACE2 “supernatant transfer” experiments were conducted. Supernatants 
from neither the WT nor MUT BACE2 overexpressing cells had an effect on FCS-induced 
proliferation of VSMCs (Supplementary Fig. 4a). Next we analyzed whether an intracellular 
soluble fragment which could be generated by γ-secretase cleavage, subsequent to BACE2 
proteolytic cleavage, is involved in inhibition of cell growth. Pretreatment with the γ secretase 
inhibitor had also no effect on cell proliferation (99.03±3.7% vs. 100%, n.s, Supplementary 
Fig. 4b). Together, these data indicate that the growth-inhibiting factor/s generated by 
BACE2 is/are not released into the cell supernatant or cytoplasm. 
2. MANUSCRIPT DRAFT   
 70
 
BACE2 Inhibits Pro-Inflammatory Signaling Pathways 
To investigate different signaling pathways possibly contributing to the BACE2-mediated 
anti-proliferatory effect, phosphorylation kinetics of key molecules shown to play a role in the 
regulation of VSMCs cell proliferation were determined using bioplex array system. A 
decrease in phosphorylation, was observed in WT BACE2 overexpressing cells for c-jun (-
41±11.3%, P=0.022, Fig. 4a) and IκB-α (-31±5.3%, P=0.01, Fig. 4b) after 30 min of FCS 
stimulation compared to control cells. In the other proteins investigated (CREB, GSK-3 α/β, 
IRS-1, p70 S6 Kinase, ERK1/2 and p38 MAPK) no effect of BACE2 overexpression on 
phosphorylation kinetics was observed (Supplementary Fig. 5).  
Next we determined gene expression levels of the pro-inflammatory molecules IL-6, IL-1β 
and cox2 in untreated and FCS stimulated cells.  
In untreated cells expression of IL-6, IL-1β and cox2 was at a low level and not affected by 
BACE2 overexpression. Stimulation with FCS resulted in an increased gene expression of at 
least 2-fold and BACE2 overexpression resulted in a 27±10% (P=0.031, Fig. 4c) and 26±10% 
(P=0.039, Fig. 4c) decrease in expression of IL-6 and cox2 compared to CTL cells, 
respectively. IL-1β was not affected by BACE2 overexpression. This result indicates that 
decreased phosphorylation of c-jun and IκB may result in decreased expression of the pro-
inflammatory genes IL-6 and cox2 in VSMCs. 
 
BACE2 Overexpression Also Decreases pro-Inflammatory Gene Expression and 
Additionally Atherosclerotic Lesions in ApoE-/- Mice  
To study the functional role of BACE2 in an in vivo model of atherogenesis, we generated a 
mouse expressing a human WT BACE2 transgene under the control of a chicken actin 
promotor allowing ubiquitous expression of the gene. Heterozygote mice were used for 
experiments. Steady state mRNA expression levels of BACE2 were 3-fold higher in aortas of 
ApoE-/- BACE2-Tg mice compared to ApoE-/- control mice (Supplementary Fig. 1b). To 
investigate whether in an in vivo experimental setting expression of pro-inflammatory genes is 
also affected by BACE2 overexpression, steady state mRNA expression levels of VCAM-1, 
IL-6, IL-1β, cox2 and TNF-α were analyzed in aortic tissue by real-time PCR. In the first 
treatment group, mice were fed with control diet and sacrificed at 10 weeks of age. 
Expression levels of the inflammatory genes IL-6, IL-1β and TNF-α in the thoracic aorta were 
at a low level, whereas cox2 was expressed about 10-fold higher (Fig. 5a) and no differences 
amongst the two mice strains were observed. At this stage no atherosclerotic plaques were 
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observed in the aorta of both ApoE-/- and ApoE-/- BACE2-Tg mice (24, and data not shown). 
In the second treatment group, mice were subjected to an additional high-fat, cholesterol diet 
for 15 weeks at the age of 10 weeks. All genes analyzed were 2 to 10-fold higher expressed 
compared to the control diet group (Fig. 5a, b). In thoracic aorta of ApoE-/- BACE2-Tg mice 
expression of IL-1β was decreased by 56% and of cox2 by 53% compared to control ApoE-/- 
mice (Fig. 5b), whereas expression of IL-6 and TNF-α was similar across groups. In these 
mice atherosclerosis was quantified by measuring oil red O-stained areas representing lipid-
rich, atherosclerotic plaques in longitudinally opened aortas. As shown in Fig. 5c and 5d 
overexpression of WT BACE2 decreased total lesion area by 28% (23.8±1.4% in ApoE-/- 
mice to 17.2±1.7% lesion areas in ApoE-/- BACE2 Tg mice, P=0.006).  Atherosclerotic 
plaques were slightly more abundant in the abdominal compared to thoracic region of the 
aorta, but in both parts plaque areas were significantly decreased in the ApoE-/- BACE2-Tg 
mice (abdominal aorta: 18.8±2.3% vs. 27.3±2.3%, P=0.014; thoracic aorta: 15.8±1.9% vs. 
21.4±1.6%, P=0.032, Fig. 5d). Together, these data suggest that BACE2 decreases the 
formation of atherosclerotic lesion and inhibits the expression of pro-inflammatory proteins in 
the aorta. 
 
Decreased Plasma Levels of Lipids and Pro-Inflammatory Cytokines in the Presence of 
BACE2 Transgene 
Levels of pro-inflammatory cytokines in the blood plasma were analyzed. IL-1β levels were 
downregulated by 44% (P=0.037) and a trend towards downregulation for IL-6 (-33%, 
P=0.17) and TNF– (-40%, P=0.06) was observed suggesting a systemic anti-inflammatory 
effect of BACE2 transgene expression (Fig. 6a). In line with these data, plasma levels of 
cholesterol (-11%, P= 0.0006), triglycerides (-41%, P= 0.0001), and free fatty acids (-25%, 
P= 0.016) were also downregulated in this group (Fig. 6b). Lipoprotein profiles as analyzed 
by FPLC indicated less abundancy of VLDL and LDL in the plasma of ApoE-/- BACE2-Tg 
mice (-41%, Fig. 6c). No difference between groups was observed in regard to body weight, 
relative glucose tolerance and plasma insulin levels (Supplementary Table 5). 
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DISCUSSION 
 
The present study demonstrates for the first time a role of BACE2 in atherogenesis and in the 
regulation of human VSMCs cell proliferation. In these cells, which are importantly involved 
in atherosclerosis development 5, we detected BACE2 in the plasma membrane and 
throughout all secretory membrane compartments including Golgi apparatus/TGN and early 
endosomes, a distribution pattern which was similarly demonstrated in neuronal cells and 
other cell types 22, 39, 41. Endocytic organelles constitute of a complex network of subcellular 
compartments, which are actively involved in transport to and uptake of membrane-associated 
signaling molecules from the plasma membrane thereby controlling signal transduction. 
Intriguingly, our data also indicate that BACE2 is co-localized with caveolin-1 and is found in 
the triton-insoluble cell compartment, indicating that BACE2 resides in lipid rafts as 
demonstrated for its homologue BACE1 46, 47. Lipid rafts are small platforms of tightly packed 
lipid bilayer composed of sphingolipids and cholesterol coordinating and regulating a variety 
of signaling processes 48. This suggests that BACE2 may play a role in raft-originating 
intracellular signaling pathways.  
To characterize the potential role of BACE2 in atherosclerosis, functional aspects of the 
disease such as cell proliferation and plaques development were analyzed. We speculated that 
in healthy condition, BACE2 may act as a gate keeper to maintain VSMCs in a quiescent, 
contractile phenotype, whereas in diseased condition, BACE2 may be downregulated 
allowing phenotype switching to a proliferative, synthetic phenotype characteristic for 
vascular disorders like atherosclerosis. Frequently, downregulation/degradation of proteins is 
mediated via proteasomal pathways which have been shown to be overstimulated in 
atherosclerosis 49. Since our data showed decreased expression of BACE2 in atherosclerotic 
tissues in vivo (unpublished observation) as well as a FCS-dependent degradation of BACE2 
in VSMCs via proteasomal pathways in vitro, it is possible that decreased BACE2 expression 
is a result of overstimulated proteasomal pathways. This may be a mechanism to further 
promote the atherosclerotic process via increased VSMCs proliferation. A similar 
expressional regulation has been demonstrated for hyperplasia suppressor gene/mitofusin-2 
which inhibits serum-mediated VSMCs proliferation and is downregulated during 
atherogenesis 40.  
In order to investigate how BACE2 could mediate inhibition of cell proliferation we tested 
two possible mechanisms. First, being the antiproliferative effect of BACE2 secretase-
dependent, we investigated whether the proteolytic activity of BACE2 was responsible for the 
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release of ligands into the supernatant that are involved in growth inhibition. This mechanism, 
known as ectodomain shedding, is already demonstrated for many ligands such as PDGF, 
EGF and TNF-α 45. However, supernatants from BACE2 overexpressing cells had no 
additional effect on VSMCs proliferation indicating that the growth-inhibiting factor/s is/are 
unlikely to be released into the cell supernatant. Secondly, we tested whether γ-secretase 
cleavage, subsequent to BACE2 proteolytic cleavage, was involved in inhibition of cell 
growth. Rationale for this hypothesis was the instance of plasma membrane-bound Notch 
which transmits signals to the nucleus by γ-secretase-dependent release of a intracellular 
fragment regulating in that way gene transcription 50. BACE2 cleaves APP preferentially at an 
alternative α-secretase site, resulting in soluble APP (sAPP) and a C-terminal part (APP CTF) 
which remains bound to the membrane. This membrane-bound APP CTF is further processed 
by a γ-secretase, generating a small peptide (p3), which is secreted, and a C-terminal fragment 
(CTFγ), which is released into the cytoplasm 41, 51. Due to the fact that γ-secretase inhibition 
had no effect on cell proliferation it appears unlikely that CTFγ of APP or proteolytically 
cleaved cytoplasmic domains of so far unknown substrates of BACE2 are involved in growth 
inhibition. Together, our data indicate that proteolytic activity of BACE2 is not involved in 
generation of intra- or extracellular fragments which directly block cell proliferation.  
Inflammation is often associated with proliferation of VSMCs which promotes atherosclerosis 
development 3. Analyzing intracellular signaling pathways after FCS stimulation we found 
that VSMCs overexpressing BACE2 showed reduced phosphorylation of the c-jun, an integral 
part of the dimeric transcription factor AP-1, and IκBα, an inhibitor of the transcription factor 
NF-κB, indicating a reduced activation of the pro-inflammatory transcription factors AP-1 
and NF-κB 15, 52. Indeed, we observed after stimulation with FCS a low but significant 
decrease in gene expression of pro-inflammatory molecules such as interleukin 6 (IL-6) and 
cyclooxygenase 2 (cox2) in cells overexpressing BACE2. Both genes are known to be under 
transcriptional control of NF-κB 53, 54 and AP-1 54, 55 in VSMCs. Cox2 is an inducible enzyme 
responsible for the synthesis of prostanoids (such as prostaglandins, prostacyclins and 
thromboxanes) and is known to be involved in inflammatory processes including 
atherosclerosis 56. IL-6 is a pro-inflammatory cytokine, which has an important impact on cell 
proliferation and atherosclerotic plaques development 57, 58.  
Looking at inflammation in our mouse model of atherosclerosis, we could show that mice 
which were free of atherosclerotic lesions expressed very low levels of pro-inflammatory 
cytokines in the aorta independent of BACE2 protein amount. However, upon high-fat diet 
treatment, the analyzed cytokines were expressed at a higher level, and, in support to our in 
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vitro data, transgenic mice showed more then 50% reduced expression of cox2 and of the pro-
inflammatory growth-promoting cytokine interleukin 1β (IL-1β) 59, 60. IL-1β concentration 
was also found to be strongly reduced in the plasma of the same mice. Interestingly, binding 
of IL-1β to its receptor mediates activation of both NF-κB and AP-1 transcription factors 61 
leading to transcription of many genes responsible for proliferation and inflammation. IL-1β 
binds to IL-1 receptor type I (IL-1RI), which is also known to be expressed in VSMCs 60 and 
to IL-1RII. Proteolytic cleavage of the extracellular part of IL-RI 62 and IL-RII 18 has been 
demonstrated, whereof IL-1RII can be cleaved by BACE2 18. Moreover, it has been shown 
that antagonizing IL-1β signaling, suppresses atherosclerotic lesion development in ApoE-
deficient mice 63. Our data, showing a reduced expression of pro-inflammatory genes in 
VSMCs overexpressing BACE2 and in aorta of ApoE-/-, BACE2-Tg mice suggest a 
connection between BACE2-mediated reduction of cell proliferation and inflammation. 
Currently, we are analyzing whether IL-1 receptor type I is cleaved by BACE2 in VSMCs, 
resulting in “receptor decapitation” and therefore in the downregulation of the downstream 
signaling pathways.  
In support to our gene expression data from aortic tissue, Fernandez-Hernando and co-worker 
also showed using ApoE-/- and ApoE-/-, Akt-/- mice, that differences in atherosclerosis-related 
gene expression depend on high-fat diet 64. This indicates that besides modification of the 
mouse genotype a strong atherogenic stimulus such as high-fat/cholesterol diet is needed to 
identify expressional differences in atherosclerosis-related genes. Our in vivo data are 
compatible with the notion that BACE2 expression is strongly involved in the downregulation 
of pro-inflammatory gene expression. In vitro, on the contrary, the effects were rather small 
suggesting that either different cell types (i.e. macrophages or endothelial cells) or a distinct 
VSMC phenotype (closer resembling highly activated VSMCs found in atherosclerotic 
lesions) contribute to the decreased expression of pro-inflammatory cytokines in the plasma 
and in the aorta of BACE2 transgenic mice.  
An elevated level of LDL cholesterol is one of the most important risk factor for the 
development of atherosclerosis 2. As BACE2 transgene expression lowered the level of the 
LDL cholesterol fraction by more than 40% it is highly likely that this dramatic decrease 
contributes to the decreased atherosclerotic lesion size in the aorta. Further studies are 
warranted to analyze the underlying cellular and molecular mechanism by which BACE2 
regulates cholesterol and lipid metabolism.  
In conclusion, our data suggest for the first time a role of BACE2 in the regulation of 
proliferation and inflammation in VSMCs in vitro. Additionally, BACE2 appears to be 
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involved in the inhibition of atherosclerotic plaques development by regulating plasma levels 
of pro-inflammatory cytokines and lipids in vivo. Interestingly, it has been shown that patients 
with trisomy 21 have a slower progression of atherosclerotic vascular changes compared to 
controls throughout the cardiovascular system 65. This observation may be explained by a 
protective role of BACE2 due to a gene dosis effect as BACE2 is located on chromosome 21 
at position 21q22.3 in human 17, which is the critical region of the Down syndrome (trisomy 
21). Thus, the specific induction and activation of BACE2 could provide a novel therapeutic 
approach to decrease progression of atherosclerosis. 
 
Acknowledgement 
Supported by grants of the Swiss National Science Foundation (3200-108258/1 and K-
33KO122504/1 to M.B.) and by the University of Zurich. The authors thank Dr. Lutz 
Wolfram for critical reading of the manuscript and for his scientific suggestions; Dr. Michael 
Farzan for BACE plasmids; Dr. Markus Niessen for sharing equipment, Prof. Dr. Erling Falk 
for critical discussion and help in atherosclerosis quantification, and Dr. Pawel Pelczar for 
performing the micro-injections of oocytes.  
 
Contributions: 
MB and EH designed the study; MB, EH and RM projected the experiments; EH and RM 
wrote the manuscript; MB, EH and RM interpreted the results and performed statistical 
analysis; RM, EH, EA and AP performed in vitro experiments, EH, PC and RM generated 
transgenic mice; RM, EH, IB and MD performed mice experiments; CW measured plasma 
levels of cholesterol, lipids and insulin and performed FPLC analysis; AP measured metabolic 
parameters of the mice. 
 
 
 
 
 
2. MANUSCRIPT DRAFT   
 76
References 
 
1. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104(4):503-516. 
2. Illingworth DR, Durrington PN. Dyslipidemia and atherosclerosis: how much more 
evidence do we need? Curr Opin Lipidol. 1999;10(5):383-386. 
3. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115-
126. 
4. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and 
early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28(5):812-
819. 
5. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and 
atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 
2002;8(11):1249-1256. 
6. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth 
muscle cell differentiation in development and disease. Physiol Rev. 2004;84(3):767-
801. 
7. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J 
Cardiol. 2003;91(3A):3A-6A. 
8. Avogaro A, de Kreutzenberg SV, Fadini GP. Oxidative stress and vascular disease in 
diabetes: is the dichotomization of insulin signaling still valid? Free Radic Biol Med. 
2008;44(6):1209-1215. 
9. Kamiya K, Sakakibara K, Ryer EJ, Hom RP, Leof EB, Kent KC, Liu B. 
Phosphorylation of the cyclic AMP response element binding protein mediates 
transforming growth factor beta-induced downregulation of cyclin A in vascular 
smooth muscle cells. Mol Cell Biol. 2007;27(9):3489-3498. 
10. Stawowy P, Blaschke F, Kilimnik A, Goetze S, Kallisch H, Chretien M, 
Marcinkiewicz M, Fleck E, Graf K. Proprotein convertase PC5 regulation by PDGF-
BB involves PI3-kinase/p70(s6)-kinase activation in vascular smooth muscle cells. 
Hypertension. 2002;39(2 Pt 2):399-404. 
11. Rothwarf DM, Karin M. The NF-kappa B activation pathway: a paradigm in 
information transfer from membrane to nucleus. Sci STKE. 1999;1999(5):RE1. 
12. Takahashi E, Berk BC. MAP kinases and vascular smooth muscle function. Acta 
Physiol Scand. 1998;164(4):611-621. 
13. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and 
transformation. Biochim Biophys Acta. 1991;1072(2-3):129-157. 
14. Breslow JL. Mouse models of atherosclerosis. Science. 1996;272(5262):685-688. 
2. MANUSCRIPT DRAFT   
 77
15. Zhang N, Ahsan MH, Zhu L, Sambucetti LC, Purchio AF, West DB. Regulation of 
IkappaBalpha expression involves both NF-kappaB and the MAP kinase signaling 
pathways. J Inflamm (Lond). 2005;2:10. 
16. Khachigian LM, Fahmy RG, Zhang G, Bobryshev YV, Kaniaros A. c-Jun regulates 
vascular smooth muscle cell growth and neointima formation after arterial injury. 
Inhibition by a novel DNA enzyme targeting c-Jun. J Biol Chem. 
2002;277(25):22985-22991. 
17. Solans A, Estivill X, de La Luna S. A new aspartyl protease on 21q22.3, BACE2, is 
highly similar to Alzheimer's amyloid precursor protein beta-secretase. Cytogenet Cell 
Genet. 2000;89(3-4):177-184. 
18. Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C, Lichtenthaler SF. Regulated 
intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and 
gamma-secretase. J Biol Chem. 2007;282(16):11982-11995. 
19. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, 
Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, 
Christie G. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol 
Cell Neurosci. 1999;14(6):419-427. 
20. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, 
Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, 
Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers 
G, Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the 
transmembrane aspartic protease BACE. Science. 1999;286(5440):735-741. 
21. Basi G, Frigon N, Barbour R, Doan T, Gordon G, McConlogue L, Sinha S, Zeller M. 
Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 
on beta-amyloid peptide production in cells. J Biol Chem. 2003;278(34):31512-31520. 
22. Yan R, Munzner JB, Shuck ME, Bienkowski MJ. BACE2 functions as an alternative 
alpha-secretase in cells. J Biol Chem. 2001;276(36):34019-34027. 
23. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. BACE2, a beta -secretase 
homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-
beta precursor protein. Proc Natl Acad Sci U S A. 2000;97(17):9712-9717. 
24. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice 
develop lesions of all phases of atherosclerosis throughout the arterial tree. 
Arterioscler Thromb. 1994;14(1):133-140. 
25. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia 
and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258(5081):468-
471. 
26. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-
specific expression of transgenes delivered by lentiviral vectors. Science. 
2002;295(5556):868-872. 
27. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression 
transfectants with a novel eukaryotic vector. Gene. 1991;108(2):193-199. 
2. MANUSCRIPT DRAFT   
 78
28. MacLeod DC, Strauss BH, de Jong M, Escaned J, Umans VA, van Suylen RJ, Verkerk 
A, de Feyter PJ, Serruys PW. Proliferation and extracellular matrix synthesis of 
smooth muscle cells cultured from human coronary atherosclerotic and restenotic 
lesions. J Am Coll Cardiol. 1994;23(1):59-65. 
29. Locher R, Brandes RP, Vetter W, Barton M. Native LDL induces proliferation of 
human vascular smooth muscle cells via redox-mediated activation of ERK 1/2 
mitogen-activated protein kinases. Hypertension. 2002;39(2 Pt 2):645-650. 
30. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic 
smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci U S A. 
1986;83(3):674-678. 
31. Andrau D, Dumanchin-Njock C, Ayral E, Vizzavona J, Farzan M, Boisbrun M, 
Fulcrand P, Hernandez JF, Martinez J, Lefranc-Jullien S, Checler F. BACE1- and 
BACE2-expressing human cells: characterization of beta-amyloid precursor protein-
derived catabolites, design of a novel fluorimetric assay, and identification of new in 
vitro inhibitors. J Biol Chem. 2003;278(28):25859-25866. 
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408. 
33. Pichon S, Bryckaert M, Berrou E. Control of actin dynamics by p38 MAP kinase - 
Hsp27 distribution in the lamellipodium of smooth muscle cells. J Cell Sci. 
2004;117(Pt 12):2569-2577. 
34. Brinster RL, Chen HY, Trumbauer ME, Yagle MK, Palmiter RD. Factors affecting the 
efficiency of introducing foreign DNA into mice by microinjecting eggs. Proc Natl 
Acad Sci U S A. 1985;82(13):4438-4442. 
35. Wilmut I, Hooper ML, Simons JP. Genetic manipulation of mammals and its 
application in reproductive biology. J Reprod Fertil. 1991;92(2):245-279. 
36. http://jaxmice.jax.org/pub-
cgi/protocols/protocols.sh?objtype=protocol&protocol_id=221. 
37. Mundy AL, Haas E, Bhattacharya I, Widmer CC, Kretz M, Hofmann-Lehmann R, 
Minotti R, Barton M. Fat intake modifies vascular responsiveness and receptor 
expression of vasoconstrictors: implications for diet-induced obesity. Cardiovasc Res. 
2007;73(2):368-375. 
38. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL 
formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat 
Med. 2005;11(4):418-422. 
39. Hussain I, Christie G, Schneider K, Moore S, Dingwall C. Prodomain processing of 
Asp1 (BACE2) is autocatalytic. J Biol Chem. 2001;276(26):23322-23328. 
40. Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, Li P, Qiu X, Wen S, Xiao RP, Tang J. 
Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol. 
2004;6(9):872-883. 
2. MANUSCRIPT DRAFT   
 79
41. Fluhrer R, Capell A, Westmeyer G, Willem M, Hartung B, Condron MM, Teplow DB, 
Haass C, Walter J. A non-amyloidogenic function of BACE-2 in the secretory 
pathway. J Neurochem. 2002;81(5):1011-1020. 
42. Tanaka K. The proteasome: overview of structure and functions. Proc Jpn Acad Ser B 
Phys Biol Sci. 2009;85(1):12-36. 
43. Qing H, Zhou W, Christensen MA, Sun X, Tong Y, Song W. Degradation of BACE 
by the ubiquitin-proteasome pathway. Faseb J. 2004;18(13):1571-1573. 
44. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, 
Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D'Hooge R, Bach 
P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, De Strooper B. 
Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol 
Chem. 2005;280(35):30797-30806. 
45. Heaney ML, Golde DW. Soluble cytokine receptors. Blood. 1996;87(3):847-857. 
46. Riddell DR, Christie G, Hussain I, Dingwall C. Compartmentalization of beta-
secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol. 
2001;11(16):1288-1293. 
47. von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, Spoelgen R, 
Hshieh TT, Ranganathan S, Battey FD, Liu CX, Bacskai BJ, Sever S, Irizarry MC, 
Strickland DK, Hyman BT. The low density lipoprotein receptor-related protein (LRP) 
is a novel beta-secretase (BACE1) substrate. J Biol Chem. 2005;280(18):17777-
17785. 
48. Li XA, Everson WV, Smart EJ. Caveolae, lipid rafts, and vascular disease. Trends 
Cardiovasc Med. 2005;15(3):92-96. 
49. Herrmann J, Soares SM, Lerman LO, Lerman A. Potential role of the ubiquitin-
proteasome system in atherosclerosis: aspects of a protein quality disease. J Am Coll 
Cardiol. 2008;51(21):2003-2010. 
50. Lai EC. Notch signaling: control of cell communication and cell fate. Development. 
2004;131(5):965-973. 
51. Sun X, Wang Y, Qing H, Christensen MA, Liu Y, Zhou W, Tong Y, Xiao C, Huang 
Y, Zhang S, Liu X, Song W. Distinct transcriptional regulation and function of the 
human BACE2 and BACE1 genes. Faseb J. 2005;19(7):739-749. 
52. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol. 
2007;19(2):142-149. 
53. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene 
regulation. Am J Respir Cell Mol Biol. 1997;17(1):3-9. 
54. Viedt C, Hansch GM, Brandes RP, Kubler W, Kreuzer J. The terminal complement 
complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells 
through activation of transcription factors NF-kappa B and AP-1. Faseb J. 
2000;14(15):2370-2372. 
2. MANUSCRIPT DRAFT   
 80
55. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-
Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte 
chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-
activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287-1293. 
56. Martinez-Gonzalez J, Badimon L. Mechanisms underlying the cardiovascular effects 
of COX-inhibition: benefits and risks. Curr Pharm Des. 2007;13(22):2215-2227. 
57. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early 
atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999;19(10):2364-2367. 
58. Schieffer B, Selle T, Hilfiker A, Hilfiker-Kleiner D, Grote K, Tietge UJ, Trautwein C, 
Luchtefeld M, Schmittkamp C, Heeneman S, Daemen MJ, Drexler H. Impact of 
interleukin-6 on plaque development and morphology in experimental atherosclerosis. 
Circulation. 2004;110(22):3493-3500. 
59. Libby P, Ordovas JM, Birinyi LK, Auger KR, Dinarello CA. Inducible interleukin-1 
gene expression in human vascular smooth muscle cells. J Clin Invest. 
1986;78(6):1432-1438. 
60. Schultz K, Murthy V, Tatro JB, Beasley D. Endogenous interleukin-1 alpha promotes 
a proliferative and proinflammatory phenotype in human vascular smooth muscle 
cells. Am J Physiol Heart Circ Physiol. 2007;292(6):H2927-2934. 
61. Li X, Commane M, Jiang Z, Stark GR. IL-1-induced NFkappa B and c-Jun N-terminal 
kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK). Proc Natl 
Acad Sci U S A. 2001;98(8):4461-4465. 
62. Elzinga BM, Twomey C, Powell JC, Harte F, McCarthy JV. Interleukin-1 Receptor 
Type 1 Is a Substrate for {gamma}-Secretase-dependent Regulated Intramembrane 
Proteolysis. J Biol Chem. 2009;284(3):1394-1409. 
63. Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M, Iwakura Y, 
Ohsuzu F. Lack of interleukin-1 receptor antagonist modulates plaque composition in 
apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2004;24(6):1068-
1073. 
64. Fernandez-Hernando C, Ackah E, Yu J, Suarez Y, Murata T, Iwakiri Y, Prendergast J, 
Miao RQ, Birnbaum MJ, Sessa WC. Loss of Akt1 leads to severe atherosclerosis and 
occlusive coronary artery disease. Cell Metab. 2007;6(6):446-457. 
65. Yla-Herttuala S, Luoma J, Nikkari T, Kivimaki T. Down's syndrome and 
atherosclerosis. Atherosclerosis. 1989;76(2-3):269-272. 
 
 
2. MANUSCRIPT DRAFT   
 81
Figure Legends  
 
Figure 1: Characterization of BACE2 Constructs and Subcellular Localization of 
BACE2 in Human Vascular Smooth Muscle Cells 
a. Schematic representation of the BACE2 protein structure from N- to C-terminus. Full 
length BACE2 consists of a Signal peptide- (SP), Pro- (PO), Protease-, Transmembrane- 
(TM) and Cytoplasmic- (CP) domain. The two essential aspartic (D) catalytic residues for the 
secretase activity are indicated. 
b. Protease activity time course of membrane extracts of HEK 293T cells transiently 
transfected with wild-type (WT), mutant (MUT) BACE2 or control (CTL) constructs. 
Extracts were incubated with a FRET-competent APP-based peptide for the times indicated. 
Fluorescence intensity (FI) was recorded at 320 and 420 nm excitation and emission 
wavelengths. Data are means+SEM, n=3, *P=0.006 vs. CTL, †P=0.005 vs. MUT. 
c. HEK 293T cells transiently transfected with wild-type (WT), mutant (MUT) BACE2 or 
control (CTL) constructs were analyzed by Western blot with an antibody against BACE2.  
d. Subcellular distribution of BACE2 was analyzed in human VSMCs retrovirally transduced 
with wild-type (WT), mutant (MUT) BACE2 or control (CTL) virus constructs. Cells were 
subjected to cell fractionation and Western blot analysis using antibodies against BACE2 and 
compartment-specific proteins (α-tubulin for cytoplasma, the small G-protein Gαq/11 for 
tritron-soluble and calveolin-1 for triton-insoluble membranes). 
e. Vesicular distribution of BACE2 was analyzed in VSMCs by confocal 
immunofluorescence microscopy using an antibody against BACE2 (red) together with 
antibodies against specific marker proteins of different cell compartments (green). Co-
localization is visualized in yellow in the merged pictures. Early Endosomes were localized 
using EEA1 antibody, lysosomes using CD107a antibody, caveolae using Caveolin-1 
antibody and TGN using syntaxin antibody. Scale bars indicate 20 µm.  
 
Figure 2: Effect of Proliferative Stimuli on BACE2 Gene and Protein Expression in 
Human Vascular Smooth Muscle Cells 
a. Time course of BACE2 steady state mRNA expression levels after stimulation with LDL 
(50 μg/ml), PDGF-BB (20 ng/ml), FCS (10%) or solvent control (CTL) determined by real-
time PCR. Data are means+SEM. CT values were calculated from the gene of interest and 
the housekeeping gene β-actin, and were expressed as percentage of solvent control-treated 
cells at time-point 0 min (100%). n=4-6 per group, *P<0.0001 vs. CTL. 
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b. Incubation of VSMCs with FCS (10%) or PDGF-BB (20 ng/ml) was terminated at the 
indicated time points and cell extracts were analyzed by Western blot with antibodies against 
BACE2 and α-Tubulin as a loading control. A representative experiment out of 3 is shown.  
c. VSMCs were stimulated with FCS (10%) for the indicated time frames and cells were 
analyzed by immunofluorescence using an anti-BACE2 antibody and a TRITC-labelled 
secondary antibody. Two representative examples are shown. Scale bars indicate 20 µm. 
d. BACE2 protein expression after FCS stimulation was assessed by flow cytometry in 
unpermeabilized (Unperm= plasma membrane localized BACE2) and permeabilized (Perm= 
total BACE2) VSMCs using an antibody against the N-terminal part of BACE2 and a FITC-
conjugated secondary antibody. Upper panels: representative histograms are shown of cells 
stimulated for 0 (green), 10 (pink), and 30 min (blue) with FCS (10%), respectively. Purple 
filled histograms represent negative controls. Lower panel: BACE2 protein expression 
measured by flow cytometry. Bars represent means+SEM, n=3 per group, *P=0.017 (10 min) 
and *P=0.001 (30 min) vs. Perm unstimulated. 
e. BACE2 protein expression in VSMCs after MG-132 (10 μmol/l) and Lactacystin (20 
μmol/l) preincubation (6 h) and prior to 10% FCS stimulation (30 min) was assessed by flow 
cytometry in permeabilized cells. Bars represent means+SEM, n=4-7 per group, *P=0.002 vs. 
unstimulated, †P=0.006 (MG) and †P=0.006 (LAC) vs. FCS. 
 
Figure 3: Effect of BACE2 on Cell Proliferation in Primary Human Vascular Smooth 
Muscle Cells and in Fetal Human Aortic Smooth Muscle Cell Line  
a. Cell proliferation was measured by [3H]-thymidine incorporation assays in control (CTL), 
wild-type (WT), and mutant (MUT) BACE2 stably overexpressing VSMCs after incubation 
with 0.1 % FCS (unstimulated) or 10 % FCS for 24 h. Bars represent means+SEM and are 
expressed as percentage of FCS-stimulated CTL cells (100%), n=4 per group, *P=0.0009 vs. 
CTL, †P=0.003 vs. MUT. 
b. Cell proliferation was assessed in control (CTL), wild-type (WT), and mutant (MUT) 
BACE2 stably overexpressing FLTR cells by cell counting. Cells were counted immediately 
before starvation (white bars, day 0), after starvation for 3 days (grey bars, day 3) and after 
stimulation with 10% FCS for 2 additional days (black bars, day 5). Bars represent 
means+SEM, n=4 per group, *P=0.0005 vs. CTL, †P=0.002 vs. MUT.  
c. Cell proliferation was assessed in VSMCs transfected with BACE2 siRNA (filled bars) or 
scrambled siRNA (open bars) after stimulation with 2% or 10% FCS. Bars represent 
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means+SEM and are expressed as percentage of 10% FCS-stimulated scrambled cells 
(100%), n=4 per group, *P=0.042 (2%) and *P=0.037 (10%) vs. scrambled siRNA. 
d. Cell proliferation was assessed in VSMCs after preincubation (30 min) with a β-secretase 
inhibitor, prior to 24 h 10% FCS stimulation. Bars represent means+SEM and are expressed 
as percentage of 10% FCS-stimulated cells (100%), n=6 per group, *P=0.002 vs. FCS 
stimulation alone. 
 
Figure 4: Effects of BACE2 on Signaling Pathways Involved in Inflammation in Human 
Vascular Smooth Muscle Cells 
Protein phosphorylation of c-Jun (a) and IКB-α (b) was assessed using Bioplex protein array 
system in control (CTL, open symbols) and wild-type (WT, filled symbols) BACE2 stably 
overexpressing human VSMCs after 10% FCS stimulation at the indicated time points. 
Phosphorylation was normalized to protein content. In the left panels the time course of 
protein phosphorylation is shown after stimulation with 10% FCS and expressed as 
percentage of CTL0 min. In the right panels the different phosphorylation status at time point 
30 min are expressed as percentage of CTL30 min. Bars represent means+SEM, n=4-5 per 
group, (a) c-jun *P=0.022 and (b) IКB-α *P=0.01 vs. CTL. 
c. Steady state mRNA expression levels of IL-6, IL-1β and cox2 were determined in control 
(open bars) and wild-type BACE2 overexpressing cells (black bars) using real-time PCR. 
Cells were left untreated (left panel) or FCS stimulated (right panel). Data are means+SEM. 
CT values were calculated from gene of interest and housekeeping gene β-actin and are 
expressed as percentage of control cells stimulated with FCS (100%). n=4 per group, IL-6 
*P=0.031 and cox2 *P=0.039 vs. CTL. 
 
Figure 5: Effects of BACE2 Overexpression on Atherosclerosis Development and on the 
Expression of Pro-Inflammatory Genes in the Aorta of ApoE-/- Mice 
a./b. Steady state mRNA expression levels of IL-1, IL-1β, cox2 and TNF-α were analyzed by 
real-time PCR in the thoracic aorta of ApoE-/- (open bars) and ApoE-/- BACE2-Tg (black 
bars) mice after control diet (a) or high fat/cholesterol (b) diet. Data are means+SEM. CT 
values were calculated from gene of interest and housekeeping gene β-actin; n=2-4 per group. 
c. Representative atherosclerotic plaques staining (red colour) of longitudinally opened aortas 
(en face analysis) using Oil red O staining in ApoE-/- and ApoE-/- BACE2-Tg mice after high 
fat/cholesterol diet.  
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d. Quantification of atherosclerotic lesion area in total, thoracic and abdominal aorta in ApoE-
/- and ApoE-/- BACE2-Tg mice. Data represent means+SEM and are expressed as percentage 
of thoracic, abdominal, or total aorta area, respectively, ApoE-/- (n=27), ApoE-/- BACE2-Tg 
(n=13), *P=0.006 (total aorta), *P=0.031 (thoracic aorta) and *P=0.014 (abdominal aorta) vs. 
ApoE-/- mice. 
 
Figure 6: BACE2-Tg Expression Reduces Plasma Levels of Pro-Inflammatory 
Cytokines and Lipids after High-Fat/Cholesterol Diet  
a./b. Plasma levels of the pro-inflammatory cytokines IL-1β, IL-6 and TNF- (a; n=9 per 
group.) cholesterol and lipids (b; n=10 per group) were quantified in fasted ApoE-/- (open 
bars) and ApoE-/- BACE2-Tg mice (filled bars). CHL: cholesterol, TG: triglycerides, FFA: 
free fatty acids. Data represent means+SEM, (a) IL-1β *P=0.037 vs. ApoE-/- and (b) CHL 
*P=0.0006, TG *P=0.0001, FFA *P=0.016 vs. ApoE-/-.  
c. Lipoprotein profiles measured by FPLC analysis in fasted ApoE-/- (open bars) and ApoE-/- 
BACE2-Tg mice (filled bars) mice. Data represent lipoprotein profile of pooled plasma from 
10 animals.  
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Supplementary Information 
 
1. Material and Methods 
 
Supplementary Table 1: Oligonucleotides Used for Cloning 
 
 
     Name                                Forward primer     
                                                                                                 Reverse  primer 
 
forD110A    5’-GCTACAGATTCTCGTTGCTACTGGAAGCAGTAACTTTGCCG-3’ 
revD110A   5’-CGGCAAAGTTACTGCTTCCAGTAGCAACGAGAATCTGTAGC-3’ 
forD303A   5’- GCCATCGTGGCTAGTGGCACCACGCTGC-3’ 
revD303A   5’-GCAGCGTGGTGCCACTAGCCACGATGGC-3’ 
forXbaI      5’-CAATGCTCTAGAGCCACCATGGGCGCACTGGCCCGG-3’ 
revBamHI  5’-CAATGCGGATCCTCAGCGGGTTTAAACGGGCCC-3’ 
forSalI        5’-ACGGGTCGACGCCACCATGGGCGCACTGGCCCGGGCGCTGCTGC-3’ 
revHindIII 5’-AAGCAAGCTTGTCATTTCCAGCGATGTCTGACCAGAGAGG-3’ 
forLinker   5’-AATTCGCCGTCGACTATAAGCTTCGCG-3’ 
revLinker  5’-AATTCGCGAAGCTTATAGTCGACGGCG-3’ 
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Supplementary Table 2: Primers Used for Amplification of Human cDNA 
 
         Gene                                    Forward primer     Product size 
accession number                       Reverse  primer           (bp) 
 
BACE2                    5`-GAT TCTCGT TGACACTGGAAG CA-3`         113 
AF178532               5`-CAAAGCCCTTGGAGCGGTATG-3` 
 
IL-6            5'-TTCGGTCCAGTTGCCTTC-3'          132 
NM_000600             5'-TCGTTCTGAAGAGGTGAGTG-3' 
 
IL-1β            5'-TTACAGTGGCAATGAGGATGAC-3'            128 
NM_000576             5'-AGTGGTGGTCGGAGATTCG-3' 
 
Cox2            5'-CCCTGAGCATCTACGGTTTG-3'         107 
AY462100                5'-CATCGCATACTCTGTTGTGTTC-3' 
 
TNF-α           5'-AAGGACACCATGAGCACTG-3'           118 
NM_000594             5'-AGAAGAGGCTGAGGAACAAG-3' 
 
 
 
Supplementary Table 3: Primers Used for Amplification of Mouse cDNA 
 
         Gene                                    Forward primer     Product size 
accession number                       Reverse  primer           (bp) 
 
BACE2                    5’-GCAGAGAGTATAACGCAGACAAGG-3’           78 
NM_019517            5’-CATCAAACACCTTCTGGGGCAG-3’ 
 
IL-6           5'-CCATCCAGTTGCCTTCTT G-3'                    139 
NM_031168           5'-AATTAAGCCTCCGACTTGTG-3'  
 
IL-1β    5'-GCTTCAGGCAGGCAGTATC-3'         133 
NM_008361   5'-AGGATGGGCTCTTCTTCAAAG-3' 
 
Cox2    5'-GCGAGCTAAGAGCTTCAGG-3'         121 
NM_011198   5'-GAAGAGCATCGCAGAGGTG-3' 
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Supplementary Table 4: Primers Used for the Genotyping of Mice 
 
 
     Name                                Forward primer     
                                                                                                 Reverse  primer 
 
CAG                                      5'-GGG TTC GGC TTC TGG CGT G-3' 
BACE2                                  5’-TCCTGCCACGGCAAAGTT-3’ 
oIMR0180                             5'-GCCTAGCCGAGGGAGAGCCG-3' 
oIMR0181                             5'- TGTGACTTGGGAGCTCTGCAGC-3' 
oIMR0182                             5'- GCCGCCCCGACTGCATCT -3' 
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Supplementary Table 5: Metabolic Parameters in ApoE-/- and ApoE-/- BACE2-Tg Mice 
After 15 Weeks of High-Fat Diet 
 
 
    ApoE-/-                                     ApoE-/- BACE2-Tg 
 
 
Body weight (g)                  28.8 ± 0.4    (28)                   28.5 ± 0.5      (11)                   
 
Glucose (AUC)             1732.7 ± 59.4  (31)     1621.2 ± 80.3   (17) 
 
Insulin (ng/ml)        0.343 ± 0.03  (10)                 0.341 ± 0.02    (10) 
 
 
Glucose tolerance tests were performed prior to sacrifice and body weight was measured 
immediately before experiments in ApoE-/- and ApoE-/- BACE2-Tg Mice. Glucose tolerance is 
presented as area under the curve (AUC) generated on the basis of glucose measurements 
from 0 to 120 min after intraperitonal glucose injection. Fasting insulin levels from both 
groups were determined after 15 weeks of high-fat diet feeding. Data represent means+SEM, 
n-numbers are indicated in brackets.  
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2. Supplementary Figures 
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Supplementary Figure 1: pCAG-BACE2 Mammalian Expression Vector and 
Overexpression of BACE2 in the Carotis and Aorta of Transgenic Mice 
a. Schematic representation of the pCAG-BACE2 mammalian expression vector. The vector 
consists of the human BACE2 sequence (h_BACE2; red) controlled by the chicken β-actin 
promoter (blue) and followed by a polyA tail (yellow). The prokaryotic parts of the vector are 
represented in light blue and are needed for replication in bacterial cells (pBR322 ori and the 
ampicilin resistance gene). 
b. Steady state mRNA expression levels of BACE2 in carotid artery (CA), thoracic aorta 
(TA), heart (H), muscle (M), lung (L), brain (B), kidney (K), liver (Li) and spleen (S) from 
ApoE-/- and ApoE-/- BACE2-Tg mice after high fat/cholesterol diet analyzed by real-time 
PCR. Data are means+SEM. CT values were calculated from gene of interest and 
housekeeping gene β-actin; n=3-4 per group. 
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Supplementary Figure 2: Overexpression of BACE2 in Fetal Human Aortic Smooth 
Muscle Cell Line (FLTRs) and in Human Vascular Smooth Muscle Cells (VSMCs) 
Cell extracts from VSMCs and FLTRs retrovirally transduced with control (CTL), wild-type 
(WT) or mutant (MUT) BACE2 expressing viruses, were analyzed by Western blot using 
antibodies against BACE2 and α-Tubulin as loading control.  
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Supplementary Figure 3: Downregulation of BACE2 Gene and Protein Expression after 
siRNA Transfection in Human Vascular Smooth Muscle Cells 
Upper panel: BACE2 steady state mRNA expression levels were determined using real-time 
PCR in VSMCs after transfection with BACE2-specific (black bars) and scrambled (white 
bar) siRNA. CT values were calculated from gene of interest and housekeeping gene β-actin 
and are expressed as percentage of scrambled transfected cells (100%).  
Lower panel: Cell extracts from BACE2-specific and scrambled siRNA transfected VSMCs 
were analyzed by Western Blot using antibodies against BACE2 and α-Tubulin as loading 
control.  A representative experiment out of 3 is shown. 
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Supplementary Figure 4: No Direct Role of Soluble Fragments Generated by BACE2 in 
Inhibition of Cell Proliferation 
a. Cell proliferation was assessed by [3H]-thymidine incorporation assays in VSMCs treated 
with culture supernatants of control (CTL), wild-type (WT) or mutant (MUT) BACE2 stably 
overexpressing VSMCs. After supernatant transfer cells were stimulated with 2% FCS for 24 
h (black bars) or kept unstimulated (white bars). Bars represent means+SEM and are 
expressed as percentage of 2% FCS-stimulated CTL cells (100%), n=5 per group. 
b. Cell proliferation was assessed in VSMCs after preincubation (30 min) with a -secretase 
inhibitor, prior to 24 h 10% FCS stimulation. Bars represent means+SEM and are expressed 
as percentage of 10% FCS-stimulated cells (100%), n=3 per group. 
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Supplementary Figure 5: No Effect of BACE2 Overexpression on Phosphorylation of 
Signaling Molecules 
CREB, GSK-3 α/β, p70 S6 Kinase, ERK1/2, IRS-1 and p38 MAPK phosphorylation was 
assessed using Bioplex protein array system in control (CTL, open symbols) and wild-type 
BACE2 (WT, filled symbols) stably overexpressing human VSMCs after 10% FCS 
stimulation for the indicated time frames. Phosphorylation was normalized to protein content. 
Bars represent means+SEM and are expressed as percentage of CTL0 min, n=4-5 per group. 
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3. EXPERIMENTS NOT INCLUDED IN THE MANUSCRIPT DRAFT 
 
3.1 In Vitro Experiments 
 
3.1.1 Introduction  
 
In the manuscript draft presented in this thesis, a modulatory effect of BACE2 on VSMCs 
proliferation and on pro-inflammatory gene expression was observed. However, the 
mechanisms how BACE2 mediates these effects remain unclear. In this part of the study, 
some mechanistic hypotheses were tested in more detail. 
 
3.1.2 Methods  
 
Ion-Exchange Fractionation of Cell Supernatants  
Cell supernatants were collected, filtered trough a 0.45 μm filter, and applied on HiTrap QFF 
ion-exchange columns (GE-Healthcare, Zurich, Switzerland). The fractions were eluted using 
increasing concentrations of NaCl (from 100 mM to 1 M) in 20 mM triethanolamine pH 8 
according to the manufacturer’s guidelines. Before adding the purified eluted fractions to 
VSMCs, the samples were desalted using PD-10 desalting columns (GE-Healthcare, Zurich, 
Switzerland). 
 
Stimulation of VSMCs with Growth Factors 
VSMCs (50% confluent) were starved for 24 h (0.1% FCS) followed by stimulation with 
hepatocyte growth factor (HGF, RELIATech, Braunschweig, Germany), growth hormone 
(GH, Alexis Biochemicals, Lausen, Switzerland), Insulin-like growth factor-1 (IGF-1, Sigma-
Aldrich, Deisenhofen, Germany) or epidermal growth factor (EGF, Sigma-Aldrich, 
Deisenhofen, Germany) for 18 h, followed by (methyl-3H)-thymidine incorporation assay as 
described in the manuscript draft. 
 
Coomasie Blue Analysis of Cell Supernatant  
Cell Supernatant from BACE2 (WT), BACE2 (MUT) overexpressing VSMCs and from CTL 
cells were collected and proteins were concentrated using Amicon Ultra-10K Centrifugal 
Filter Devices (Millipore, Zug, Switzerland). Protein concentration was measured by Bradford 
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method and equal amounts of proteins were separated by electrophoresis with 10% and 12% 
SDS/PAGE gels. The gels were stained with ProtoBlue Safe Colloidal Coomassie Blue 
(National Diagnostics, Basel, Switzerland) according to the manufacturer’s guidelines. 
Differentially expressed proteins were excised from the gels and sequenced by mass 
spectrometry (performed by the Genomic center, University of Zurich, Zurich). 
 
3.1.3 Results  
 
Role of Cell Supernatant on Inhibition of Cell Growth  
To investigate the potential role of soluble factors in the supernatant of BACE2 
overexpressing cells for the inhibition of cell proliferation, “supernatant transfer” experiments 
were performed. Supernatants of BACE2 (WT), BACE2 (MUT) overexpressing VSMCs and 
of CTL cells were transferred onto untransduced VSMCs and cell proliferation experiments in 
the presence of 2% FCS were performed. As already presented in the Supplemental Figure 4 
of the manuscript draft, supernatants from neither the wild-type nor the secretase-inactivated 
BACE2 overexpressing cells had an effect on VSMCs proliferation, indicating that the 
growth-inhibiting factor/s is/are unlikely to be released into the supernatant. To exclude that 
the factor(s) was (were) missed due to too low concentration, supernatants were concentrated 
and fractionated by ion-exchange column. As shown in Figure 11, each fraction had different 
proliferative property but no difference between supernatant from CTL and WT cells was 
observed. 
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Figure 11: Effect of concentrated cell supernatant on cell proliferation in human VSMCs 
Cell proliferation was assessed in untranduced VSMCs treaded with different fractions of cell 
supernatant from control (CTL) and wild-type BACE2 (WT) overexpressing VSMCs. Cell supernatants 
were fractionated by HiTrap QFF ion-exchange columns, followed by desalting using PD-10 columns. 
Bars represent means+SEM and are expressed as percentage of unstimulated cells, n=4 per group. 
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Effect of BACE2 Overexpression on Growth Factor-Dependent Cell Proliferation 
Since a putative BACE2-dependent ectodomain shedding of a growth factor receptor was 
speculated, BACE2 (WT), BACE2 (MUT) overexpressing VSMCs and CTL cells were 
stimulated with different specific growth factors followed by cell proliferation assay. Basal 
proliferation was unchanged between groups (data not shown). Stimulation with HGF and GH 
had no effect on VSMC proliferation (Figure 12). Only after EGF and IGF-1 stimulation, a 2 
to 3-fold increase in cell proliferation was observed, but BACE2 overexpression had no effect 
(Figure 12). 
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Figure 12: Effect of BACE2 on Growth Factors-Dependent Cell Proliferation in Human Vascular 
Smooth Muscle Cells. Cell proliferation was measured by [3H]-thymidine incorporation assays in 
control (CTL), wild-type (WT), and mutant (MUT) BACE2 overexpressing VSMCs after 24 h incubation 
with insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), growth hormone (GH), 
epidermal growth factor (EGF) 100ng/ml each. Bars represent means+SEM and are expressed as 
percentage of unstimulated CTL cells (100%), n=4-6 per group.  
 
Identification of Secreted and Shedded Proteins in VSMCs: Effect of BACE2 
In a second approach supernatant from BACE2 (WT), BACE2 (MUT) overexpressing 
VSMCs and from CTL cells were collected. Proteins were concentrated, separated and 
analyzed by Coomassie Blue. Bands with differential intensity between groups were further 
investigated by mass spectrometry (Figure 13).  
After protein staining with Coomassie Blue, no big differences between CTL, WT and MUT 
supernatants could be observed. However, three protein bands (a ~150 KDa, a ~90 KDa and a 
~45 KDa band, red arrows, Figure 13), could be identified to be slightly more intense in the 
supernatant from BACE2(WT) overexpressing cells. After mass spectrometry analysis and 
with the help of a Mascot Search-software, proteins present in the three bands could be 
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identified. In the band running at 150 KDa (A, Figure 13) adipocyte enhancer binding protein 
1, Isoform 1 of Fibronectin precursor and Collagen alpha-1(I) chain precursor were identified. 
In the 90 KDa band (B, Figure 13) heat shock protein 90-alpha/beta and Collagen alpha-2(I) 
were present. In the 45 KDa band (C, Figure 13) phosphoglycerate kinase 1 was identified. 
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Figure 13: Schematic representation of the experimental procedure for the identification of 
proteins shedded into the supernatant. Supernatant from control (CTL), wild-type (WT), and mutant 
(MUT) BACE2 stably overexpressing VSMCs were collected and protein concentrated. After protein 
separation using 10% and 12% SDS/PAGE gels, proteins were stained by Coomassie Blue. 
Differentially expressed proteins (red arrows) were excised out of the gels, proteolitically digested and 
analyzed by liquid chromatography (LC), electrospray ionization (ESI) and mass spectrometry (MS). 
Results were analyzed by Mascot Search program. 
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3.1.4 Discussion  
 
In this part of the study hypotheses regarding the potential mechanisms how BACE2 is 
modulating cell proliferation and pro-inflammatory gene expression in VSMCs were tested.  
Supernatants from BACE2(WT), BACE2(MUT) and CTL VSMCs had no differential effect 
on VSMCs, neither in unconcentrated or concentrated form. These results suggest no role of 
BACE2-dependent shedded ligand/s in inhibition of cell proliferation. 
The second hypothesis investigated in this part of the thesis was a putative BACE2-dependent 
post-translational downregulation of a growth receptor by ectodomain shedding. In a first 
approach, WT, MUT and CTL VSMCs were stimulated with different specific growth factors 
and proliferation was monitored. If BACE2 was responsible of cleaving the specific receptor 
for the investigated ligand, a reduced proliferation of WT cells could be expected. The ligands 
chosen are known to be involved in atherosclerosis and their specific receptors are already 
described to exist in soluble form. HGF and its receptor c-met are known to be expressed by 
VSMCs and have the capability to stimulate their proliferation and migration, two important 
feature of atherosclerosis development. C-met was also described to exist in a truncated 
soluble form, by the action of metalloprotease shedding 1. Evidences that GH regulates 
VSMCs proliferation also exist 2, 3 and interestingly, it was shown that GH receptor undergoes 
metalloproteolytic cleavage resulting in receptor loss of function 4. EGF has been 
demonstrated to be a potent mitogen in VSMCs and to be highly atherogenic 5 partly 
contributing to induction of VSMCs dedifferentitation 6. The EGF receptor ErbB1 was also 
described to be proteolytic processed by metalloproteases 7. Finally, binding of IGF-1 to its 
tyrosine kinase receptor activates a number of mitogenic pathways, leading to cell growth 8. 
Also in VSMCs IGF-1 results in VSMCs migration and proliferation 9. A protease-dependent 
ectodomain shedding was observed for IGF-1 receptor as well 10. 
Surprisingly, stimulation with HGF, GH and EGF was not inducing proliferation of VSMCs. 
This may be explained by a technical limitation of the approach used in this experiment, or by 
a putative absence of the receptors for the chosen ligands. Passaging of cultured cells is 
known to induce deterioration of plasma membrane receptors 11. The expression of cyclin 
GMP-dependent protein kinase receptor, for example, was described to decrease upon VSMC 
passaging 12. For this reason, it may be possible that the VSMCs used for this experiment lost 
the receptors for the chosen growth factors during culture. To complete this analysis receptor 
expression of the ligands used in this study should be verified on protein level. Together, it 
should be noted that until further analysis are performed no conclusion could be drown. 
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In a second approach proteins present in the supernatant of CTL, WT and MUT VSMCs were 
separated by gel electrophoresis, and bands were visualized by Commassie Blue and analyzed 
using mass spectrometry to identify differences in shedded proteins. The differences 
identified by this approach were minimal, and the proteins assigned to the bands further 
analyzed by LC/ESI/MS/MS have probably no relevance for the mechanism hypothesized. 
Fibronectin 13 and Collagen 14 in fact are extracellular matrix protein, secreted by the cell 
mainly to fulfill structural function. Heat shock protein 90 was already demonstrated by Liao 
et al. to be secreted (and not shedded) by VSMCs under proliferative/stress conditions 15, and 
phosphoglycerate kinase 1, one of the enzyme involved in glycolysis, was also showed to be 
secreted 16. Additionally, both proteins were identified at the molecular weight equivalent to 
the original full-size of the protein (90 and 45 KDa respectively). The same was observed for 
the ~175 KDa adipocyte-enhancer binding protein 1, a transcriptional repressor protein 
known to be involved in VSMC differentiation 17; also in this case the protein was found at 
the expected molecular size as the full length protein. In conclusion, none of the proteins 
identified in this approach is a product of BACE2-dependent shedding, as all proteins 
analyzed were secreted. The assay chosen to test this hypothesis was probability not sensitive 
enough. A possible strategy to enhance sensitivity in this approach may be a pre-selection of 
the protein to be analyzed. Since the extracellular domains of shedded proteins are usually 
glycosylated 18, a good strategy may be to enrich and analyze only glycosylated peptides. This 
may eliminate from the analysis high abundant secreted proteins and therefore it may render 
small differences more visible. The use of 2D gel elecrophoresis instead of a normal one-
dimensional SDS/PAGE gel and the labeling of amino acids with fluorescent dyes, may also 
help the identification of putative extracellular shedded product. The same was for instance 
done by Bech-Serra and co-workers 19 to analyze culture supernatant of ADAM17 
overexpressing cells. 
In conclusion, the experiments presented in this part of the thesis are still preliminary and do 
not allow any conclusion.  
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3.2 In Vivo Experiments 
 
3.2.1 Introduction  
 
In the manuscript draft presented in this thesis, I characterize the effect of BACE2 
overexpression in ApoE-/- mice. In these mice the amount of atherosclerotic plaques and blood 
plasma concentrations of the pro-inflammatory cytokine IL-1β, cholesterol and lipids were 
reduced. It may be therefore interesting to characterize the effect of BACE2 secretase 
inactivation in the same animals. For this reason ApoE-/- BACE2-/- and control ApoE-/- mice 
were analyze in this part of the study. 
 
3.2.2 Methods  
 
Generation of C57BL/6J ApoE-/- BACE2-/- Mice Lacking BACE2 Catalytic Activity  
BACE2 secretase-inactivated mice (BACE2-/-) were kindly provided by Prof. Bart De 
Strooper and Prof. Paul Safting from the Center for Human Genetics, K.U Leuven and 
Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium; and Christian 
Albrechts University, Kiel, Germany. These mice lack exon 6, containing one of the two 
aspartic catalytic residues indispensable for secretase activity. The mice were generated by 
Cre/lox P recombination technique introducing two lox P sites in the intron flanking exon 6 as 
described in 19. 
BACE2-/- mice were back-crossed into C57BL/6J using speed congenics 20 and then crossed 
with C57BL/6J ApoE-/- to generate homozygous C57BL/6J ApoE-/- BACE2-/- mice. 
Genotyping of the mice for the BACE2 locus was performed using primers                        
5'-GCTATAGAGACCAAAGCCCACAAATCT-3' and 5'-GCCCGAATAACAAGAGCATCAC-3’.  
For the ApoE locus oIMR0180, oIMR0181 and oIMR0182 primers (primers listed in the 
Supplementary Table 4 of the manuscript draft) were used. 
Housing and experimental procedure are described in the method section of the manuscript 
draft. 
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Metabolic Parameters, Cholesterol and Lipid Measurements 
Body weights, fasting glucose levels, plasma level of cholesterol, triglycerides, free fatty 
acids and insulin, and the separation of plasma lipoproteins by FPLC were performed as 
described in the method section of the manuscript draft. 
 
Quantification of Atherosclerosis 
Atherosclerotic plaques of ApoE-/- and ApoE-/- BACE2-/- mice were visualized using oil red O 
staining as described in the method section of the manuscript draft. 
 
Cytokines Detection 
IL-1β, IL-6 and TNF-α cytokine levels were quantified in the plasma of ApoE-/- and ApoE-/- 
BACE2-/- mice using the Bio-PlexTM suspension array system kit according to the 
manufacturer’s guidelines. 
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3.2.3 Results  
 
Inactivation of BACE2 Secretase Activity Does Not Affect the Development of 
Atherosclerotic Lesions in the Aorta of ApoE-/- Mice 
To further investigate the function of BACE2 in atherosclerosis development in vivo, we 
generated ApoE-/- mice lacking BACE2 secretase activity (ApoE-/- BACE2-/-). In the aorta of 
these mice and of control ApoE-/- mice atherosclerotic lesions, represented by lipid-rich area, 
were visualized in red after oil red O-staining (Figure 14a). As shown in Figure 14b 
inactivation of BACE2 secretase activity had no effect on lesion formation neither in the 
thoracic (21.4±1.6% ApoE-/- vs. 20.5±2.3% ApoE-/- BACE2-/-, n.s) nor in the abdominal aorta 
(27.3±2.3% ApoE-/- vs. 23.8±2.1% ApoE-/- BACE2-/-, n.s).  
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Figure 14: Effect of BACE2 secretase inactivation on atherosclerosis development in the aorta 
of ApoE-/- mice after high-fat/cholesterol diet. 
a. Representative images of atherosclerotic plaques from longitudinally opened aortas (en face 
analysis) using oil red O staining in ApoE-/- and ApoE-/- BACE2-/- mice after high fat/cholesterol diet.  
b. Quantification of atherosclerotic lesion area in total, thoracic and abdominal aorta in ApoE-/- and 
ApoE-/- BACE2-/- mice. Data represent means±SEM and are expressed as percentage of thoracic, 
abdominal, or total aorta, respectively. ApoE-/- (n=27) and ApoE-/- BACE2-/- (n=20). 
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Inactivation of BACE2 Secretase Activity Does Not Affect the Level of Pro-
Inflammatory Cytokines, Lipids and Cholesterol in the Plasma of ApoE-/- Mice 
The level of pro-inflammatory cytokines in the plasma of ApoE-/- BACE2-/- and control  
ApoE-/- mice were analysed. IL-1β, IL-6 and TNF-α were detected in the plasma of both 
animal groups. IL-6 was 2-fold higher expressed (at about 40 pg/ml, Figure 15a) compared 
with IL-1β and TNF-α, which were expressed at around 20 pg/ml (Figure 15a). No difference 
in cytokine levels were observed between groups.  
The level of cholesterol, triglycerides and free fatty acids were also analysed. The 
concentration of total cholesterol in the plasma of these mice was at about 525 mg/dl, which is 
7-fold higher compared with the triglycerides concentration. Free fatty acids level was 
ranging from 580 to 600 μM. No difference in cholesterol, triglyceride and free fatty acid 
levels between ApoE-/- BACE2-/- and control ApoE-/- mice were observed (Figure 15b).  
The lipoprotein profile of both animal groups was analysed more in detail by FPLC analysis. 
The level of VLDL was producing the higher pick, reaching a concentration of about 0.65 
mg/dl. LDL was 2-fold less concentrated (0.3 mg/dl) compared with VLDL. The level of the 
anti-atherogenic HDL was almost undetectable in both animal groups. No difference in 
lipoproteins was detected between ApoE-/- BACE2-/- and control mice using FPLC analysis 
(Figure 15c).  
 
3. EXPERIMENTS NOT INCLUDED IN THE MANUSCRIPT DRAFT   
110 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
5 10 15 20 25 30 35 40 45
CHL TG FFA 
0
50
100
500
600
700
0
50
100
500
600
700
µM
m
g/
dl
40
30
20
10
50
pg
/m
l
b
a
IL-1ß IL-6             TNF-α
0
c
Fraction number
LDL
HDL
VLDL
C
ho
le
st
er
ol
 (m
g/
dl
)
 
 
Figure 15: Effect of BACE2 secretase inactivation on plasma levels of pro-inflammatory 
cytokines, cholesterol and lipids after high-fat/cholesterol diet. 
a. Plasma levels of IL-1β, IL-6 and TNF-α inflammatory cytokines were quantified in fasted ApoE-/- 
(open bars) and ApoE-/- BACE2-/- (filled bars) mice. Data represent means+SEM. n=9 per group. 
b. Cholesterol (CHL), triglycerides (TG) and free fatty acids (FFA) were quantified in the plasma of 
fasted ApoE-/- (open bars) and ApoE-/- BACE2-/- (filled bars) mice. Data represent means+SEM. n=10 
per group. 
c. Lipoprotein profiles measured by FPLC analysis in fasted ApoE-/- (open symbols) and ApoE-/- 
BACE2-/- (filled symbols) mice. Data represent lipoprotein profile of pooled plasma from 5 animals.  
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Effect of BACE2 Secretase Inactivation on Metabolic Parameters in ApoE-/- Mice 
Body weight of ApoE-/- BACE2-/- and control ApoE-/- mice was monitored. Prior to sacrifice 
ApoE-/- BACE2-/- mice showed 5% higher body weight compared with ApoE-/- mice 
(30.4±0.31 vs. 28.9±0.4, P=0.013, Figure 16a). 
Glucose tolerance test was also performed in these mice. Mice with inactivated BACE2 
catalytic activity had a better glucose tolerance as represented in Figure 16b (AUC: 
1288.7±52.4 vs. 1732.7±59.4, P<0.0001). The insulin level in the plasma of both animal 
groups was ranging between 0.3 and 0.35 ng/ml, but no significant difference was observed 
between ApoE-/- BACE2-/- and control ApoE-/- mice (Figure 16c).  
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Figure 16: Effect of BACE2 secretase inactivation on metabolic parameters in ApoE-/- mice after 
high-fat/cholesterol diet. 
a. Body weight was measured prior to sacrifice in fasted ApoE-/- (open bars) and ApoE-/- BACE2-/- 
(filled bars) mice. Data represent means+SEM. ApoE-/- (n=28) and ApoE-/- BACE2-/- (n=19), *P=0.013 
vs. ApoE-/- mice. 
b. Glucose tolerance tests were performed prior to sacrifice in fasted ApoE-/- (open symbols) and 
ApoE-/- BACE2-/- (filled symbols) mice. Data represent means+SEM. ApoE-/- (n=31) and ApoE-/- 
BACE2-/- (n=21), AUC *P<0.0001 vs. ApoE-/- mice. 
c. Insulin plasma level was quantified in fasted ApoE-/- (open bars) and ApoE-/- BACE2-/- (filled bars) 
mice. Data represent means+SEM. n=10 per group. 
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3.2.4 Discussion  
 
In this part of the study the effect of BACE2 secretase inactivation on atherosclerotic plaque 
formation, plasma level of inflammatory cytokines and metabolic parameters were examined 
in vivo. To do that, we analyzed ApoE knock-out mice lacking one of the two aspartic 
catalytic residues indispensable for BACE2 secretase activity 21 (ApoE-/- BACE2-/-) after 
feeding the animals with a high fat/cholesterol diet.  
Inactivation of BACE2 secretase activity had no effect on atherosclerotic plaque formation, 
plasma concentration of pro-inflammatory cytokines and plasma levels of cholesterol and 
lipids such as triglycerides and free fatty acids. Body weight, on the contrary, was slightly 
increased in ApoE-/- BACE2-/- mice compared to control ApoE-/- mice. The small difference is 
probably not relevant for the present study but rather a consequence of experimental 
variability. Surprisingly, glucose tolerance was significantly improved in the ApoE-/-    
BACE2-/- compared to control mice, despite a similar fasting plasma insulin concentration. 
The ameliorated glucose tolerance in these mice led to speculate a putative role of BACE2 in 
glucose metabolism. It is well known that the sensitivity to the glucose-lowering action of 
insulin is very variable 22. It may be possible that the absence of BACE2 activity in the   
ApoE-/- BACE2-/- mice improves the sensitivity to insulin. To be able to confirm this 
hypothesis, an insulin tolerance test should be performed. Binding of insulin to its receptor 
stimulates the uptake of glucose into the cells 23, and BACE2 may possibly interfere with 
insulin-mediated signalling pathways leading to inhibition of glucose uptake. Skeletal muscle 
and/or adipose tissue are the major organs involved in storage and metabolism of glucose 23. 
For instance, shedding of the transmembrane protein TNF-α receptor 2 has been negatively 
correlated with insulin sensitivity 24, suggesting a possible mechanistic link to our result. 
Further studies on that direction should be done to test this hypothesis.  
In the manuscript draft previously presented a decrease in atherosclerotic plaque formation 
and a reduction in plasma concentration of inflammatory cytokines, cholesterol and lipids in 
ApoE-/- mice overexpressing BACE2 was observed. Having established that BACE2 had a 
protective role in these mice, one may expect an aggravation of the overall condition in regard 
to atherosclerosis in mice lacking BACE2 secretase activity. Surprisingly, this was not 
observed in our ex-vivo experiments. It can not be excluded, that the apparent normal 
phenotype of ApoE-/- BACE2-/- mice is due to a compensatory mechanism and/or genetic 
redundancy. Another protein able to compensate the role of BACE2 may be present in these 
mice to balance the lack in secretase activity. This phenomenon was demonstrated in mice 
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lacking the gene for calcium transport, CaBP-9K 25. These mice showed no distinct phenotype 
compared to wild-type suggesting the presence of compensatory genes. Given that BACE2 
has a high homology with BACE1 26, and that both proteins share frequently the same 
substrate 26, 27, BACE1 may be the best candidate to compensate for the absence of catalytic 
activity of BACE2. A partially compensatory role of BACE1 and BACE2 was already 
demonstrated by Dominguez and co-workers in a previous study 21. To analyze a possible 
overlapping function of the two homologous proteases, this group generated mice with 
inactivated BACE1, BACE2 or both secretase activities. This study demonstrated a higher 
mortality rate in mice having BACE1 secretase inactivated. On the contrary, and in support to 
our results, mice lacking BACE2 activity showed an overall healthy phenotype. Interestingly, 
double knock-out mice, had an higher mortality rate than the monogenic secretase inactive 
mice, suggesting a compensatory mechanism between the two homologous genes 21. 
Therefore, a compensatory role of BACE1 may be speculated in the present as well. To be 
able to demonstrate this hypothesis, ApoE-/- mice lacking both BACE1 and BACE2 secretase 
activities should be generated and analyzed for atherosclerosis development and for other 
metabolic parameters. Considering the fact that double knock-out mice showed a higher rate 
of mortality in the study of Dominguez et al. 21, the creation of the ApoE-/- BACE1-/-   
BACE2-/- mice may not be feasible or recommended.  
Other secretases apart from BACE1 could also be considered as good candidates to 
compensate the activity of BACE2 in the ApoE-/- BACE2-/- mice. α-Secretases of the ADAM-
family, such as ADAM-17 28, ADAM-10 29, ADAM-9 30 and ADAM-19 31 were for example 
shown to cleave APP in the non-amylogenic pathway similarly to BACE2 32, 33.  
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4. EXTENDED DISCUSSION 
 
4.1 Regulation of BACE2 Expression  
 
In the present thesis, a proteasome-dependent degradation of BACE2 upon mitogenic stimuli 
was observed. This is a commonly used regulatory mechanism to rapidly downregulate 
cellular proteins. Transmembrane proteins such as PDGF, GH and EGF receptors have also 
been shown to be downregulated by this pathway 1. Proteins with antiproliferative function, 
such as tumor suppressor p53, were described to be downregulated by the proteasome in 
many tumor cells in order to initiate cell cycle 2. Similarly it has been shown in the present 
study. Since the downregulation of BACE2 observed after mitogenic stimuli is still present 
after 48h, it is highly possible that the rapid degradation of BACE2 protein is followed by a 
further regulation at transcriptional level. This is supported by the data presented in the 
manuscript draft, which show a decrease in BACE2 expression at mRNA level as well.  
A better characterization of BACE2 on transcriptional level may help to achieve a more 
complete understanding of its regulation in VSMCs. The nucleotide sequence of BACE2 
promoter was analyzed by different groups and potential consensus sequences of transcription 
factors were identified 3-5. However, the in silico data generated should be further analyzed in 
vitro to identify DNA-binding proteins (transcription factors), which may possibly interact 
with the BACE2 promoter or enhancers regions. This could be investigated by performing 
assays such as electrophoretic mobility shift (EMSA), DNase I footprinting assay and 
chromatin immunoprecipitation assay (ChIP) 6. The transcription factors identified using this 
approaches may be validated in VSMCs. 
 
4.2 BACE2, an Alternative α-Secretase: Role of α-Secretases in 
Atherosclerosis 
 
As described in the introduction of this dissertation, α-secretases 7 including BACE2 8, 9 
prevent Alzheimer’s disease by participating in the non-amylogenic processing of APP. 
BACE2 in fact was described to preferentially cleave APP between phenylalanine 190 and 
phenylalanine 191, which is 3 amino acids after the α-secretase cleavage site 9. Enzymes of 
the ADAM family belong to the category of the α-secretases. Dependent on the cell type, 
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ADAM proteins have a variety of physiological functions, including regulation of cell growth, 
migration, signalling and homeostasis 10. Not surprisingly, these proteins, being involved in so 
many processes, are also linked to different diseases such as cancer, Alzheimer’s disease and 
cardiovascular diseases 10. During atherosclerosis, ADAM proteins are shown to be 
importantly involved in the inflammatory processes by inducing ectodomain shedding of 
different transmembrane proteins 10. In leukocytes, metalloprotease-dependent shedding of L-
selectin, is known to inhibit leukocytes adherence to the endothelial cells 11, thereby 
preventing rolling and emigration of these cells into the arterial wall. Shedding of ICAM-1 
and V-CAM-1 by ADAM-1712, on the contrary, is promoting leukocyte-rolling. VE-cadherin 
shedding by ADAM-10 13 enhances vascular permeability for leukocytes, by disturbing 
intracellular junction of endothelial cells 12. ADAM-17 also mediates extracellular shedding 
of cytokines such as pro-TNF-α, regulating inflammatory responses during atherogenesis 14. 
Moreover, metalloproteaseas such as ADAMDEC1 are also involved in plaque destabilisation 
by proteolitically cleaving the extracellular matrix of an advanced fibrous lesion 14. Notch 
signalling activation triggered by sequential ADAM and γ-secretase cleavage resulting in the 
released of an intracellular domain, is known to activate macrophages, which then express 
high amounts of inflammatory molecules 15.  
It is evident that α-secretases are involved in many biological processes, and that their 
function is much dependent from the molecular context of their expression. The same should 
also be considered for BACE2. The role of this aspartyl protease observed in VSMCs in this 
study, may in fact differ significantly at different stage of atherosclerosis or in other cell 
types. 
 
4.3 Possible Role of BACE2 in Cytokine Receptor Shedding  
 
In the present study a reduced activation of AP-1- and NF-κB-dependent pro-inflammatory 
signaling pathways in VSMCs overexpressing BACE2 were observed. These transcription 
factors are frequently activated via binding of pro-inflammatory cytokines to their cognate 
receptors 16, 17. 
Interestingly, the IL-1 receptor type II (IL-1R2), a decoy receptor homologous to IL-1RI 
transmembrane receptor, has been identified as a substrate of BACE2 18. Recently, Elzinga 
and co workers demonstrated that IL-1R1 undergoes proteolytic processing 19. Binding of IL-
1β to IL-1R1 mediates activation of both NF-κB and AP-1 transcription factors 20 and, 
importantly, this cytokine receptor is known to be expressed in VSMCs 21 and also to be 
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localized in lipid rafts 22, as shown in this thesis for BACE2. A prior study suggests α- β- and 
γ-secretases-mediated cleavage to occur preferentially in these membrane compartments 23. 
The possible BACE2-mediated shedding of IL-1R1 and IL-1R2 may increase the availability 
of decoy receptors in the blood plasma and lead to a loss of receptor function. These 
mechanisms may be responsible for the downregulation of intracellular c-jun- and IκBα-
dependent pro-inflammatory and mitogenic signaling cascade. Figure 17 depicts a schematic 
representation of the putative role by which BACE2 mediates downregulation of cytokine 
receptor signaling.  
 
Cytokine
Cytokine 
receptor 
BACE2
BACE2low high
c-jun and NF-κB
cell signaling
Cell growth
Inflammation
 
 
Figure 17: Model for BACE2-dependent downregulation of pro-inflammatory pathways and 
proliferation. Shedding of the extracellular part of a cytokine receptor by BACE2 may result in 
downregulation of downstream pro-inflammatory signaling pathways, inhibiting the transcription of 
inflammatory and mitogenic molecules. 
 
The speculation that IL-1R1 and/or Il-1R2 decapitation is/are involved in the anti-atherogenic 
action of BACE2 is supported by the observation that IL-1 induces expression of adhesion 
molecules in endothelial cells 24 and promotes proliferation in VSMCs 25, underscoring the 
importance of IL-1 during atherogenesis 25. However, is very likely that other receptor/s 
involved in inflammation and proliferation in addition to IL-1R1 is/are cleaved by BACE2. 
Therefore, an unbiased substrate screening approach of the entire cell proteome may help to 
identify BACE2 substrates responsible for the phenotype observed in VSMCs. 
Today, the development of tools to compare proteomes quantitatively enables the 
identification of differences occurring from genetic or treatment disparity 26. In a recent study 
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Hemming and co-workers identified γ-secretase substrates by metabolically labeling cellular 
amino acids with heavy or light isotopes 27. Subsequently, the membrane proteins from 
control cells and cells treated with a γ-secretase inhibitor were separated using SDS-PAGE 
and analyzed by mass spectrometry, which differentiates between heavy and light isotopes.  
A possible approach to identify putative substrates of BACE2 responsible for the anti-
atherogenic properties observed in our study could be to perform a general substrate screening 
using control and BACE2 overexpressing VSMCs. A comparative proteomic analysis of the 
culture supernatant of control and VSMCs overexpressing BACE2 may also give important 
evidence for shedded products. This approach was used to identify new substrates of the 
metalloprotease ADAM17 28, where conditioned medium derived from ADAM17 
overexpressing cells treated with or without a metalloprotease inhibitor was subjected to 
agarose chromatography and the purified glycoproteins were labeled with Cy3 or Cy5 and 
analyzed by 2D gel electrophoresis. Spots differing in intensity were excised and processed 
by ionization mass spectroscopy to identify proteins. Alternatively, instead of analyzing 
shedded proteins present in the cell supernatant, the membrane fraction of the cells could be 
analyzed by mass spectrometry, to identify extracellular protein domains which are missing in 
cells overexpressing BACE2. A similar approach was used by Lund and co-workers to 
identify metastasis-associated cell surface markers 29. In this study surface membrane proteins 
of metastatic and non-metastatic cell line were isolated and separated by density gradient, 
followed by a dual stable isotopic labeling by amino acids (SILAC) of the proteomes. Mass 
spectrometry analysis was used to identify and quantify proteins that were differentially 
expressed. The identification of a potential substrate of BACE2 in VSMCs, which may 
explain the mechanism involved in the anti-atherogenic action of the secretase, may give 
important information to mechanistically explain the results described in the present thesis. 
 
4.4 In vivo relevance? 
 
To investigate whether the effect of BACE2 observed in VSMCs has in vivo relevance, the 
effect of overexpression and secretase inactivation of BACE2 was analyzed in a well 
established mouse model of atherosclerosis: the apolipoprotein E knock-out mouse (ApoE-/-). 
These mice develop spontaneously hypercholesterolemia and atherosclerotic plaques 30, 31. For 
the in vivo experiments performed in this study, only male mice were used, as estrogen was 
shown to reduce lesion formation in ApoE-/- mice 32. 
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The transgenic mice generated in this study overexpress human BACE2 protein. Importantly, 
the amino acid sequence of human and murine BACE2 shares 88% identities, whereby the 
two catalytic regions are completely orthologous as verified by blast analysis. Therefore it 
appears highly likely that human and murine BACE2 proteins have highly similar substrate 
recognition sites.  
In the in vivo experiments we demonstrated a reduction in atherosclerotic plaque area and in 
plasma concentration of pro-inflammatory cytokine IL-1β in ApoE-/- mice overexpressing 
BACE2 (ApoE-/- BACE2-Tg). Surprisingly, the opposite effect was not observed in mice 
lacking BACE2 secretase activity (ApoE-/- BACE2-/-). As already discussed (see: discussion 
part of the in vivo experiments not included in the manuscript draft), a compensatory 
mechanism may be involved. It is important to consider that the choice of the duration of the 
high fat/cholesterol diet treatment may influence considerably the in vivo results. The 
atherosclerotic plaques that were observed in ApoE-/-, ApoE-/- BACE2-Tg and ApoE-/- 
BACE2-/- mice after 15 weeks of high fat/cholesterol diet treatment are already at an advanced 
stage. Performing the in vivo experiments at an earlier time point, may allow to delineate 
differences between mice strains.  
Importantly, the results generated in vivo are compatible with the in vitro observations and 
with the hypothesis of IL-1R1 and IL-1R2 decapitation. In fact, activation of this cytokine 
receptor is known to amplify the inflammatory response by expressing different cytokines, 
including IL-1 itself. This may explain the reduced concentration of IL-1 in the plasma of 
BACE2-Tg mice. Considering that the transgenic mice generated in this study overexpress 
BACE2 ubiquitously and that IL-1 and IL-1R1 are produced by different cells involved in the 
pathogenesis of atherosclerosis 33, the involvement of other cells other than VSMCs in the 
anti-atherogenic effect of BACE2 is highly likely.  
It would be interesting to generate mice overexpressing BACE2 specifically in VSMCs. The 
data obtained using these mice may help to delineate which changes observed in BACE2-Tg 
mice compared to control mice are an effect of increased expression of BACE2 in VSMCs 
and which effects are mediated by other cells types. A mammalian expression vector coding 
for BACE2 under the control of a smooth muscle cell specific promoter (SM22-promoter) 
was created, however we were not able to generate a transgenic founder after nuclear injection 
of oocytes. 
It is important to consider that other cells beside VSMCs are indispensable for the 
development of an atherosclerotic lesion. Macrophages and lymphocytes are also of crucial 
importance during atherogenesis. These cells extravasate from the blood into the 
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subendothelial space, where they proliferate and contribute to the local chronic inflammation 
by releasing huge amount of cytokines 34. Definitely, it would be interesting to find out if the 
effects of BACE2 overexpression that we observed in VSMCs, may be reproduced also in 
macrophages or lymphocytes. BACE2 may in fact have a proliferation/inflammation-
regulatory role in other vascular cells in addition to VSMCs. To examine the role of 
macrophages and lymphocytes in the BACE2 transgenic mice, a bone marrow transplantation 
experiment may be performed. Bone marrow is the main hematopoietic organ which is 
responsible for the production of blood cells, including macrophages and lymphocytes 35. 
Bone marrow from ApoE-/- BACE2-Tg mice may be transplanted into control ApoE-/- mice 
followed by atherosclerotic plaque quantification. If the recipient mice show a decreased 
formation of atherosclerotic lesions, after bone marrow transplantation, this may indicate that 
bone marrow-derived cells (such as macrophages and lymphocytes) may be involved in the 
BACE2-dependent decrease in atherosclerosis development. This approach was used by Dan 
Yang and co-workers to investigate the role of adenosine receptor in VSMCs and bone 
marrow in regard to vascular injury 36. 
Additionally, since expression of the mutated BACE2 gene lacking secretase activity was 
analyzed in this study only in vitro, an interesting approach could be the generation of ApoE 
knock-out mice overexpressing BACE2 lacking secretase activity. These mice may in fact 
confirm in vivo the secretase-dependent effect of BACE2 on atherosclerosis development. 
VSMCs from these mice, BACE2 transgenic mice and ApoE-/- control mice could also be 
explanted and cultured to further perform in vitro experiments to directly link our in vitro and 
in vivo results.  
 
4.5 Possible Roles of BACE2 in Regulation of Lipid and Cholesterol 
Metabolism  
 
The decrease of the inflammatory cytokine IL1-β in the plasma of ApoE-/- BACE2 transgenic 
mice, was associated with lower cholesterol, triglycerides and free fatty acid concentrations, 
suggesting a possible role of BACE2 in the regulation of lipid and cholesterol metabolism.  
Lipids and cholesterol are insoluble in water; therefore, in the plasma these molecules are 
transported in lipoproteins such as VLDL, LDL and HDL 37. VLDL are responsible for the 
transport of triglycerides and cholesterol from the liver into the blood stream, where they are 
further catabolized to LDL. LDL molecules carry cholesterol and lipids to peripheral tissues 
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and in part to the liver. HDL have an important role in the transport of cholesterol back to the 
liver, where it may be excreted in form of bile acid 38, 39. Lipoprotein receptors play an 
indispensable role for cholesterol and lipids homeostasis by clearing these molecules from the 
blood by receptor-mediated endocytosis 38. Therefore, the transcriptional or post-translational 
regulation of receptors responsible of lipoprotein clearance is highly important. The LDL 
receptor family is composed of seven related transmembrane proteins 40. One of these 
receptors, the low-density lipoprotein receptor related protein (LRP1), is of special interest. 
LRP1 is known to be widely expressed in the body, but particularly abundant in VSMCs, 
hepatocytes and neurons 40. Moreover, LRP1 is known to undergo shedding 41. The cleavage 
of LRP1 is shown to occur through the action of BACE1 in neurons 42, and through the action 
of metalloproteases in hepatocytes 43. The biological significance of this ectodomain shedding 
is still unknown. Because BACE2 is known to cleave transmembrane protein similarly to α-
secretases metalloproteases 8, 44, and to share often the same substrate with BACE1 18, one 
could speculate a putative role of BACE2 in the cleavage of LRP1 in ApoE-/- BACE2-Tg 
mice, releasing a soluble receptor into the plasma. Moreover, in addition to lipoprotein, LRP1 
is known to bind to different ligands, such as cytokines and growth factors 45. A putative 
binding of the LRP1 soluble form (sLRP1) to pro-inflammatory cytokines present in the 
blood may therefore also be speculated. By this mechanism (“decoy receptor”) sLRP1 may 
competitively inhibit binding of inflammatory cytokines to cell-surface-bound cytokine 
receptors. The formation of complexes containing either sLRP1 and cytokine or sLRP1 and 
LDL may increase the clearance of these complexes from the plasma. Similarly, an 
involvement of LRP1 in the clearance of Aβ from the blood stream through a potential 
transport of Aβ in the liver was recently speculated 46. This hypothesis may explain the 
decreased inflammation, hypercholesterolemia and hyperlipidemia observed in ApoE-/- 
BACE2-Tg mice. Further studies in that direction should be performed to test this hypothesis. 
Interestingly, it has been shown in a recent study that processing of LRP1 limits inflammatory 
response in vitro and in vivo 47. A proteomic analysis comparing plasma of transgenic versus 
control mice may help to identify a possible substrate released into the blood circulation 
through the action of BACE2. Zhang and co-workers demonstrated that tissue-derived 
proteins are present and detectable in the plasma, using mass spectrometry analysis of 
glycopeptides 48. This technique may give the possibility to discover plasma protein 
biomarker related to diseases.  
Lipid and cholesterol metabolism are complexly regulated on transcriptional or 
posttranscriptional level 49, 50. To monitor the amount of membrane cholesterol, cells mainly 
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use transmembrane proteins with a sterol-sensing domain in the intramembrane sequence 49. 
These proteins, including Scap and HMG CoA reductase, can induce or block the de-novo 
synthesis of cholesterol by monitoring the concentration of sterol inside the cell. The de-novo 
synthesis of cholesterol is mediated by 20 different enzymes, all of which are regulated by 
SREBP transcription factor family 49. The synthesis of trigycerides and free fatty acids is also 
transcriptionally regulated and SREBP transcription factors are also known to be involved 50.  
Interestingly, and in support to our results, multiple cytokines, including IL-1, are described to 
induce lipolysis, resulting in an increased secretion of VLDL, thereby raising the levels of 
triglycerides, free fatty acids and cholesterol in the plasma. This may therefore explain the 
reduction in lipid and cholesterol plasma concentration observed in BACE2-Tg mice in 
response to the drastic decrease of IL-1 levels in the circulation. 
Being the cholesterol and lipid metabolism so highly complex, until further analysis are 
performed no conclusion can be drawn. Regulation at different levels appears likely as the 
changes observed in lipid and cholesterol concentration in the BACE2-Tg mice compared to 
control mice were dramatic.  
 
4.5 Conclusion and Clinical Implications 
 
In the present study, I showed for the first time that overexpression of BACE2 results in 
inhibition of cell proliferation and attenuation of pro-inflammatory signal cascades in 
VSMCs. On the other hand, BACE2 downregulation increased cell growth. In atherogenic 
mice, BACE2 was involved in inhibiting plaque formation, lowering plasma concentration 
levels of inflammatory cytokine IL-1β, cholesterol and lipids. Collectively, these data suggest 
a protective role of BACE2 in atherosclerosis development. For this reason, an attractive 
therapeutic approach would be to increase expression of this secretase in patients suffering 
from atherosclerosis.  
A strategy to achieve an increased BACE2 expression would be to block its proteasomal 
degradation. This could be achieved by reducing the proteasomal activity, which have been 
shown to be overstimulated in atherosclerosis 51. The development of drugs which inhibit 
protein degradation through proteasomal pathways is an intensive field of research in cancer 
treatment, where a dysregulated protein degradation is often occurring 52, 53. The discovery of 
a specific drug which specifically inhibits BACE2 proteasomal degradation may provide a 
successful therapeutic approach to decrease progression of atherosclerosis lesions or to even 
prevent their formation. 
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Gene therapy represents an additional new attractive approach in vascular medicine. 
Adenovirus-mediated fibromodulin gene transfer has been previously performed in surgically 
prepared human saphenous veins 54. Similarly, it could be possible to transduce BACE2 gene 
in vessels to be used for grafting, which may protect the grafted vessels from future lesion 
formation. 
Together, the present data give new insight of a protein, commonly perceived to be important 
in Alzheimer’s disease, as a candidate for development new therapies in atherosclerosis. 
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